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ABSTRACT
NEW INSIGHTS INTO THE ROLE OF THE UDP-GLUCOSE:
GLYCOPROTEIN GLUCOSYLTRANSFERASE 1 IN THE ENDOPLASMIC
RETICULUM QUALITY CONTROL
SEPTEMBER 2015
ABLA TANNOUS, B.S., LEBANESE UNIVERSITY
M.S., UNIVERSITY OF MASSACHUSETTS DARTMOUTH
Ph.D., UNIVERSITY OF MASSACHUSETTS AMHERST
Directed by: Professor Daniel Hebert

The UDP-glucose:glycoprotein glucosyltransferase 1 (UGT1) is a central quality
control factor in the Endoplasmic Reticulum (ER). It surveys the folding status of
proteins in the ER and redirects them, via its reglucosylation activity, to bind to the ER
carbohydrate binding (lectin) chaperones calreticulin (CRT) and calnexin (CNX).
However, the cellular mechanism of UGT1 is not completely understood. Using a cell
based reglucosylation assay, we found that UGT1 reglucosylated proteins that eventually
fold. This modification was transient and resulted in delay of protein trafficking in the
secretory pathway and prolonged binding to lectin chaperones in the ER. In addition,
terminally misfolded substrates, disease associated mutants or proteins with reduced
disulfides were reglucosylated by UGT1. Yet, this reglucosylation, despite being efficient
and persistent, did not affect their degradation by the ER-associated degradation pathway.
This suggested that degradation occurred independently of the glucose containing branch
on the substrate’s glycan. Further investigation showed that trimming mannose residues
of the substrate’s glycan is responsible for terminating the substrate reglucosylation by
UGT1 in the ER. Moreover, our preliminary data suggests that the free cysteines of the
vii

substrate might aid in its recognition and persistent reglucosylation by UGT1. Thus, our
strategy unraveled new details of the role of UGT1 in ER quality control that further
highlight its importance in protein maturation.
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CHAPTER 1
INTRODUCTION
(Sections from this chapter are adapted from (Tannous et al., 2015b))
Cellular folding
The fundamental principles of folding described by Anfinsen state that the native
structure of a protein is its most thermodynamically stable form and is dictated by its
linear amino-acid sequence (Anfinsen, 1973). While many of these principles were
acquired by studying the refolding of denatured proteins in the test tube, understanding
how proteins fold in the cellular environment is complicated by many factors. Proteins
fold in a highly crowded cellular environment, which may result in less efficient folding,
and high cellular protein concentrations can lead to aggregation. Moreover, cellular
stresses such as extreme temperatures or mutations contribute to hindering folding
efficiency. However, other cellular factors can increase folding efficiency, such as
folding co-translationally and the presence of chaperones. (Powers et al., 2009).
Folding can commence as the protein is being synthesized, thus the rate of
translation can be a determining factor in the folding pathway (Fedorov and Baldwin,
1997) (Figure 1.1). Co-translational folding limits the conformations that a protein may
sample due to its tethering to the ribosome, thus assisting the protein to more rapidly and
efficiently reach its native state (Pearse and Hebert, 2010). Additionally, chaperones and
folding enzymes largely assist cellular folding. As a result of the abovementioned factors,
even when proteins fail to fold on their own in the test tube, they could fold more
efficiently in the complex cellular environment (Rothman and Schekman, 2011).
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Protein homeostasis and diseases
Maintaining protein homeostasis is critical for retaining normal cellular functions
and its disruption can lead to disease. Some of these can be described as loss of function
diseases (Powers et al., 2009). A well-studied example is cystic fibrosis, which is caused
by reduced targeting of functional cystic fibrosis transmembrane conductance regulator
(CFTR) to the plasma membrane due to a mutation in CFTR that disrupts its folding
pathway resulting in its retention in the endoplasmic reticulum (ER) and subsequent
degradation (Jensen et al., 1995). In other instances, disease results from the abnormal
accumulation of misfolded proteins that evade the cellular degradation pathways and
result in buildup of toxic aggregates. Neurodegenerative diseases such Alzheimer’s,
Parkinson’s and Huntington’s are described as conformational diseases that are the
consequence of different forms of aggregates or cellular inclusions (Takalo et al., 2013).

Targeting to the ER and signal sequence cleavage
Approximately one third of the proteome traverses the secretory pathway, and this
begins with targeting to the ER (Stolz and Wolf, 2010). The ER is a highly specialized
and organized organelle where protein folding and quality control occur, amongst a
multitude of other vital functions. The ER harbors an arsenal of folding and quality
control factors essential to maintaining the cellular protein homeostasis network (Figure
1.1). These factors include carbohydrate binding chaperones or lectin chaperones,
classical chaperones, oxidoreductases and peptidyl prolyl isomerases, all of which
optimize folding efficiency. While properly folded proteins are targeted for ER exit to
traffic through the remainder of the secretory pathway, proteins that are deemed
2

misfolded are usually retained in the ER and are degraded through the process of ER
associated degradation (ERAD) involving the ubiquitin-proteasome system (Figure 1.1)
(Tamura et al., 2010).
Proteins that are targeted to the ER possess an N-terminal signal sequence,
constituted of approximately the first 25 amino acids (Hortsch et al., 1986; Migliaccio et
al., 1992; Braakman and Hebert, 2013). Signal sequences are recognized by the signal
recognition particle (SRP), a cytosolic ribonucleoprotein. SRP targets the
ribosome/mRNA complex to the ER by binding to the SRP receptor, an integral
membrane protein of the ER (Walter et al., 1984). The ribosome associates with the
Sec61 translocon pore (Figures 1.1 and 1.3), which allows proteins to translocate through
the pore and enter the ER lumen. Signal sequence cleavage is critical for the maturation
of a protein and is generally accepted to occur co-translationally, but may also occur
post-translationally (Braakman and Hebert, 2013; Daniels et al., 2003; Tamura et al.,
2011). The timing of signal sequence cleavage may also influence folding, as tethering a
protein to the membrane can constrain the nascent chain and help in directing the folding
process (Braakman and Hebert, 2013; Daniels et al., 2003; Tamura et al., 2011).

N-Glycans direct protein folding
Proteins that contain the consensus glycosylation site Asn-X-Ser/Thr are modified
in the ER by the addition of a 14-membered carbohydrate composed of three glucoses,
nine mannoses and two N-acetyl glucosamines (Glc3Man9GlcNAc2) (Figure 1.2). These
N-linked glycans are added en bloc by the oligosaccharyltransferase (OST) complex,
from dolichol pyrophosphate lipid carriers (Burda and Aebi, 1999) (Figure 1.3, Step 1).
3

The OST is a large multimeric complex, and the catalytic subunit of the eukaryotic OST
is STT3, which in mammals has two forms: STT3A and STT3B (Mohorko et al., 2011).
Glycans are usually added co-translationally by an OST complex containing STT3A;
however, the STT3B isoform can add glycans post-translationally on skipped sites,
usually found at the C-termini of glycoproteins (Sato et al., 2012). Of note, defects in the
glycan synthesis pathway or decreased levels of the catalytic subunit STT3B have been
associated with hypoglycosylation leading to congenital disorders of glycosylation
(CDG) (Mohorko et al., 2011; Shrimal and Gilmore, 2015).
Addition of glycans has a direct impact on the proper folding of proteins
(O'Connor and Imperiali, 1998; Hebert et al., 2014). Glycans are large hydrophilic groups
that can change the biophysical properties of the modified protein. Glycan addition may
cause the protein to sample conformations that are more compact or more closely
resemble the native structure (O'Connor and Imperiali, 1998; Imperiali and O’Connor,
1999; Chen et al., 2010). Glycans can also increase a protein’s solubility and prevent it
from forming aggregates (Sola and Griebenow, 2009). In addition, glycans can protect
proteins against proteolysis. This is proposed to be accomplished either by shielding
proteolysis sites from proteases by the glycan, or increasing the overall protein stability
(Russell et al., 2009). These properties make glycans crucial elements in the folding and
maturation of secretory proteins.

Chaperones of the ER
Chaperones that are resident in the ER are classified into two families: classical
chaperones and lectin or carbohydrate-binding chaperones. While classical chaperones
4

function independently of glycans, lectin chaperones require their presence. Classical
chaperones recognize hydrophobic regions that are usually buried in the folded form of
the native substrate. The ER contains classical chaperones from the Hsp70 and the Hsp
90 families (Brodsky and Skach, 2011). One of the most abundant chaperones in the ER
is the Hsp70 BiP (Immunoglobulin heavy chain binding protein). Hsp 70s contain a
substrate binding domain connected to a nucleotide binding domain via a linker region,
and thus their activity is regulated by binding to nucleotides, in addition to other factors
(Bukau and Horwich, 1998; Zhuravleva et al., 2012). BiP not only assists in folding but
also functions in protein translocation into the ER, activation of the unfolded protein
response (UPR) and ERAD (Hendershot, 2004) (Figure 1.1). BiP can collaborate with
chaperones from the lectin family and is proposed to act earlier in the folding process
than lectin chaperones (Hammond and Helenius, 1994; Molinari and Helenius, 2000;
Wang et al., 2005). It has also been proposed that BiP can act as a backup chaperone
when one of the lectin chaperones is absent (Pieren et al., 2005).
In contrast to classical chaperones, lectin chaperones associate with maturing
glycoproteins based on their glycan composition. The composition of the substrate’s
glycan is dynamic and incurs modifications throughout the lifetime of the protein in the
ER (Brodsky and Skach, 2011). These modifications report on the structure of the protein
and direct it to different routes. Thus, glycans are considered as a code that could
determine the fate of proteins (Figure 1.2).

5

Early trimming events and entry into the CNX/CRT cycle
As soon as the glycan is added to nascent chains, the first glucose is trimmed by
α-glucosidase I (Figure 1.3, Step 2) (Kornfeld and Kornfeld, 1985; Parodi, 2000; Deprez
et al., 2005). For a long time, the di-glucosylated form of protein-bound oligosaccharides
generated by the action of α-glucosidase I was considered an extremely short-lived
trimming intermediate lacking biological significance. The discovery of malectin, a
membrane-bound ER-resident lectin that specifically binds di-glucosylated glycans,
changed this view (Schallus et al., 2010). Malectin is induced under conditions of ER
stress (Galli et al., 2011) and is proposed to preferentially associate with off-pathway
non-native conformers of well-studied glycoproteins like influenza hemagglutinin (HA)
and null Hong Kong (NHK), a folding-defective variant of the secretory protein α-1antitrypsin (A1AT) (Galli et al., 2011; Chen et al., 2011; Qin et al., 2012). However, the
role of malectin in ER quality control is not yet well understood.
Subsequently, α-glucosidase II trims the second and the third glucose of the Nlinked glycan (Figure 1.3, steps 3 and 5). The two trimming events play opposing roles.
After the first trimming step, maturing substrates associate with the lectin chaperones
calnexin (CNX) and calreticulin (CRT), which recognize mono-glucosylated glycans.
The second trimming step releases the protein from the lectin chaperones due to the
reduced affinity of these chaperones to glycans lacking the terminal glucose residue
(Figure 1.3, step 5) (Hammond et al., 1994; Ora and Helenius, 1995; Hebert et al., 1995).
A series of de-glucosylations by α-glucosidase II (step 5) and re-glucosylations by a
glucosyltransferase, the UGT1 (step 6) can occur (Hebert et al., 1995; Cannon and
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Helenius, 1999). Re-glucosylation by UGT1 directs the rebinding of CNX or CRT to the
mono-glucosylated substrate, hence the name CNX/CRT binding cycle.

The role of the lectin chaperones CNX and CRT
CNX is a type I membrane protein. CRT is its soluble paralogue possessing 39%
sequence homology (Wada et al., 1991). CNX and CRT share similar structural
properties: they both have an N-terminal globular domain that contains the lectin binding
site, a long arm domain and require Ca2+ to function. The globular domain is a βsandwich of concave and convex β-sheets and the arm domain, shaped in an overall
hairpin like structure, is termed the P-domain (Figure 1.4). The latter protrudes 140 Å
away from the globular domain and has two different proline rich motifs named 1 and 2,
of four copies each (Schrag et al., 2001). The four copies of motif 1 on one strand interact
in a head-to-tail fashion with the four copies of motif 2 on the other strand of the hairpin
(Schrag et al., 2001). In CRT, the P-domain is similar but shorter than CNX and has three
instead of four tandem repeats (Ellgaard et al., 2002).
Despite the similarities between CNX and CRT, striking differences have been
attributed to their roles or binding specificities. The location and the number of glycans
recognized by each of the lectins could be quite distinct (Hebert et al., 1997; Harris et al.,
1998; Molinari et al., 2004). Furthermore, even though CNX and CRT share some of the
same substrates, some proteins are exclusively clients of CNX or CRT. These differences
could be assigned to their distinct topologies, as it was observed that CRT, when fused to
the membrane segment of CNX, acquired the substrate specificity of CNX (Wada et al.,
1995). Consistent with different substrate specificity and/or with specific functions in the
7

ER lumen is the fact that CNX clients seem to associate with BiP rather than with CRT
upon CNX deletion (Pieren et al., 2005) and that CNX and CRT knockouts (KO), which
are well tolerated in cultured cells, have different phenotypes in mice. CRT KO is
embryonic lethal due to defective heart development (Mesaeli et al., 1999), whereas CNX
KO mice are viable and show motor disorders, associated with a dramatic loss of large
myelinated nerve fibers (Denzel et al., 2002). Finally, the depletion of either of the lectins
may have opposing effects on folding. Depletion of CRT enhances the maturation of a
subset of viral and cellular proteins with a minor decrease in folding efficiency. To the
contrary, CNX depletion prevents the maturation of a substrate like HA, while its absence
does not affect the maturation of other proteins (Molinari et al., 2004). These differences
highlight the unique roles of each of these lectins despite their similarities.

The lectin chaperones CNX and CRT recruit folding enzymes
The lectins CNX and CRT have been demonstrated to recruit other folding
factors. One of these folding factors is ERp57, which belongs to the family of protein
disulfide isomerases (PDIs) (Figures 1.1 and 1.3). PDIs can catalyze the oxidation or
isomerization of disulfides in proteins until they reach their final correct disulfide pattern
exhibited in the native state (Oka and Bulleid, 2013; Wang et al., 2012). PDIs usually
contain thioredoxin-like domains characterized by a CXXC motif, which is responsible
for the catalytic activity. The interaction between ERp57 and lectin chaperones is
independent of the presence of client proteins further confirming that this interaction is
direct (Oliver et al., 1999). Additionally, it was suggested that ERp57 interacts with the
tip of the P-domain of the lectin chaperones (Frickel et al., 2002). Substrate folding
8

assisted by CNX and CRT is enhanced significantly in the presence of ERp57 (Zapun et
al., 1998).
Cyclophilin B (CyB), which is a member of the peptidyl prolyl isomerases (PPIs)
family (Kozlov et al., 2010), is another folding assistant that is recruited by the lectin
chaperones (Figures 1.1 and 1.3). The peptide bond of a proline can adopt a cis or trans
conformation (Di Martino et al., 2014), yet the trans conformation is slightly more
energetically favorable. An energy barrier of ~20 kcal/mol is required to allow interconversion and maintain equilibrium. PPIs assist in lowering this barrier, which
otherwise could be a rate limiting step in the folding process (Di Martino et al., 2014).
CyB, like ERp57, interacts with the tip of the CNX and CRT P-domain (Kozlov et al.,
2010). Hence, it was proposed that CyB functions in concert with the lectin chaperones
and ERp57, and is part of the CNX/CRT cycle.

The role of the folding sensor UGT1
Release from the lectin chaperones CNX and CRT is followed by trimming of the
innermost glucose residue by α-glucosidase II, which prevents immediate re-association
of the newly synthesized polypeptide to CNX and CRT. Here, a decision has to be made
whether a protein is properly folded and should be targeted for anterograde trafficking or
whether its forward transport should be prevented in order to retain it longer in the
folding environment or to select it for clearance from the ER lumen. The UDP-glucose:
glycoprotein glucosyltransferase 1 (UGT1) has been proposed to be central in this
decision making, and is described as a folding sensor because it can recognize structural
imperfections such as exposed hydrophobic domains on maturing proteins, a function that
9

is performed by its N-terminal folding sensor domain (Sousa and Parodi, 1995; Arnold
and Kaufman, 2003).
Upon recognition of structural defects on cargo proteins, the UGT1 transfers a
glucose residue onto the A branch of the glycans via its C-terminal catalytic domain
(Figure 1.3, step 6). This forces immature proteins to rebind to CNX and CRT for another
round of folding attempts under the assistance of the associated enzymes ERp57 and
CyB. Cycles of de-glucosylation and re-glucosylation occur (Hammond et al., 1994),
indicative of a role of UGT1 in retaining incompletely folded proteins in the ER (Hebert
et al., 1995; Cannon and Helenius, 1999; Wada et al., 1997; Tannous et al., 2015a).
UGT1 also contributes to the luminal retention of unassembled subunits of multimeric
complexes, thus promoting efficient and complete assembly (Keith et al., 2005).

The conservation, organization and expression of UGT1
The reglucosylation activity of UGT1 was discovered in the parasite
Trypanosoma cruzi (Parodi and Cazzulo, 1982; Trombetta et al., 1989). UGT1 is highly
conserved amongst eukaryotes including mammals, plants, fungi and protozoans.
Interestingly, UGT1 is absent from S. cerevisiae (Fernandez et al., 1994). It is a large
protein of approximately 170 kDa that possesses a signal sequence and an ER retention
sequence whose specific residues vary depending on the species (Ito et al., 2015). The
human UGT1 is highly homologous with Drosophila, C. elegans and S. pombe UGTs,
especially within the last 300 amino acid residues (Arnold et al., 2000). The homology of
the last 300 amino acids, which comprise the catalytic domain (Figure 1.5), is shared with
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bacterial glycosyltransferases (Arnold et al., 2000). The rest of UGT1 is less conserved,
and is hypothesized to be the substrate recognition or folding sensor domain (Figure 1.5).
The glycosylation status of UGT1 has not been studied extensively. While more
than one glycosylation site has been predicted, a recent study relying on mass
spectrometry suggested that UGT1 is only glycosylated on N269 (Daikoku et al., 2014)
(Figure 1.5). Although the functional relevance of this glycosylation site is not clear, its
conservation among several species, including human UGT1, points to an important role
of this glycan for the function of UGT1 (Daikoku et al., 2014). The expression pattern of
UGT1 further reinforces its physiological importance, as human UGT1 mRNA is
expressed in several tissues, but is highest in pancreatic and lowest in lungs and heart
tissues (Arnold et al., 2000). It is upregulated approximately three to four fold upon ER
stress, supporting its role in quality control of incompletely folded or unfolded proteins
that accumulate under similar ER stress conditions (Arnold et al., 2000).

The catalytic domain of UGT1
The catalytic activity of UGT1 requires high calcium concentrations (D'Alessio et
al., 2010) and implicates four residues that are essential for the glucosyltransferase
activity, Asp (D) 1452, Gln (Q) 1453, Asp (D) 1454 and Leu (L) 1455 (Arnold and
Kaufman, 2003). A DXD motif is proposed to bind to cations that are required for the
coordination of UDP-sugars in other glycosyltransferases; as a result, the DQD motif in
human UGT1 is hypothesized to be involved in a similar mechanism (Parodi, 1999)
(Figure 1.5).

11

The folding sensor domain of UGT1
There have been few insights into the structure of the folding sensor or substrate
recognition domain of UGT1. Since UGT1 recognizes substrates in a manner akin to that
of classical chaperones, it can be hypothesized that they may share similar structural
properties. Surprisingly, a recent study found that the folding sensor domain shares
structural characteristics with the class of oxidoreductases that feature domains with a
thioredoxin-like fold (Zhu et al., 2014). Homology modeling on Chaetomium
thermophilum UGT1, which shares 35% identity with human UGT1, predicted that its
folding sensor domain contains three tandem thioredoxin-like sub-domains (Zhu et al.,
2014) (Figure 1.5). The crystal structure of the third predicted thioredoxin-like domain
was solved, revealing a typical thioredoxin-like fold characterized by five β-sheets
surrounded by six helices (Zhu et al., 2014). Active thioredoxin-like domains are
characterized by a CXXC motif involved in oxidation and isomerization of disulfides.
Yet, the thioredoxin-like domains of UGT1 lack a CXXC motif, and contain only one
cysteine, which makes the functional relevance of these domains unclear. Inactive
thioredoxin-like domains have been proposed in some cases to be involved in substrate
recognition, rather than modulating the redox state of the protein (Denisov et al., 2009;
Pirneskoski et al., 2004). Thus, the inactive thioredoxin domain of UGT1 could
potentially serve a similar purpose.
UGT1 binds to a protein named Sep15, which belongs to the family of
selenocysteine containing proteins, and is the only protein identified so far to bind
directly to UGT1 (Korotkov et al., 2001; Labunskyy et al., 2005). It does not seem to be a
coincidence that Sep15 also assumes a thioredoxin-like fold. Sep15 has been proposed to
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be an active oxidoreductase (Labunskyy et al., 2007). Yet, whether Sep15 affects the
UGT1 activity has not been studied. Consequently, identifying the role of the
thioredoxin-like domains of UGT1 might unravel a previously unforeseen mechanism of
UGT1 in ER quality control that could involve Sep15.

Proposed models for substrate recognition by UGT1
Two models have been described for the mechanism of UGT1 substrate
recognition. The first model states that UGT1 is directly influenced by the structural and
biophysical properties of the peptide backbone that is proximal or local to the
reglucosylated glycan of the substrate. It was noted that UGT1 favors an alternating
peptide hydrophobicity pattern located at one to three amino acids C-terminal to the
glycan that was reglucosylated (Taylor et al., 2003). The study assayed the
reglucosylation of 24 peptides obtained from trypsin digestion of a full-length protein. In
another study, analysis of reglucosylation activity using synthetic penta-peptides
indicated that a proximal serine, C-terminal to the glycosylation site, is important for
UGT1 recognition (Kudo et al., 2014). It was anticipated that the hydroxyl-residue of the
serine might be involved in hydrogen bonding with residues in the substrate recognition
domain of UGT1, which may help stabilize the UGT1-substrate interaction. (Kudo et al.,
2014).
An investigation relying on a glycan modified with BODIPY (Borondipyrromethene), which was shown to be a good UGT1 substrate, further supported that
the neighboring glycan environment may affect UGT1 activity. In this analysis, BODIPY
consisted of the “aglycon” instead of the peptide backbone. The study demonstrated that
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the distance between BODIPY and the glycan affects UGT1 activity (Totani et al., 2009).
Upon varying the distance between the glycan and BODIPY, using increasing lengths of
polyethylene glycol (PEG) linkers, the activity of UGT1 decreased as the length of the
PEG linker increased. Moreover, other synthetic “aglycons” where tested and it was
observed that the hydrophobicity and the orientation of the aglycon portion neighboring
the glycan significantly affected the UGT1 recognition of the substrate (Totani et al.,
2009).
In contrast with the model proposing that UGT1 is directly influenced by the
properties of the peptide backbone proximal to the glycan, a study proposed that UGT1
can reglucosylate glycans that are distant from the site where UGT1 binds to the peptide
backbone of the substrate (Taylor et al., 2004). Using a substrate with a known crystal
structure, it was shown that UGT1 can recognize glycans that are 40 Å away from the
defect site, arguing for a “reach and grab” model, where UGT1 can extend to modify
glycans in folded regions (Taylor et al., 2004). These two models may not necessarily be
mutually exclusive and UGT1 may use both mechanisms to allow optimal recognition,
although this still remains to be demonstrated.

Glycan elements recognized by UGT1
Pioneering work that assessed which parts of the glycans are recognized by UGT1
proposed that UGT1 recognizes the innermost N-acetylglucosamine (GlcNAc) residue
(Sousa and Parodi, 1995). This was concluded by comparing inhibition of UGT1 activity
by EndoH or PNGase deglycosylated substrates that compete with UGT1 glycosylated
substrates. Endo-H is a deglycosylating enzyme that cleaves the bond between the two
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GlcNAc residues, leaving a protein with one GlcNAc on the asparagine. PNGase F
cleaves the bond between the innermost GlcNAc and the asparagine residue. EndoHdeglycosylated substrates were able to inhibit UGT1 activity towards glycosylated
substrates by out-competing them, suggesting high affinity for UGT1, while PNGase
treated substrates did not (Sousa and Parodi, 1995), indicating that the innermost GlcNAc
residue is the minimum glycan recognition motif for UGT1.
These observations were later supported using glycan-methotrexate conjugates as
artificial UGT1 substrates (Totani et al., 2005). When these glycans lacked the innermost
GlcNAc, UGT1 could not modify them by glucose addition (Totani et al., 2005).
Additional work using these glycan conjugates proposed that mannose residues could be
important for UGT1 recognition, as UGT1 most efficiently recognized the core
pentasaccharide Man3GlcNAc2 compared to non-mannose containing glycans (Totani et
al., 2009). The role of mannose sugars of the substrate’s glycan in UGT1 activity will be
discussed further in this manuscript.

The influence of the UGT1 localization on its role
A few studies have attempted to address the localization of UGT1 within the ER.
The ER is highly compartmentalized. A simplified classification divides the ER into
rough and smooth ER. Yet, more evidence is arising that there are additional levels of
compartmentalization, which may be mediated by complex formation, or simply by the
concentration of ER machinery in distinct regions of the ER (Leitman et al., 2013).
Based on immunofluorescence and immunogold labeling microscopy, as well as
proteomic studies, it seems as though UGT1 is more concentrated or localized in an ER
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compartment beyond the rough ER, such as the smooth ER, ER exit sites, or pre-Golgi
intermediates, and it is therefore active later in the protein maturation pathway.
Immunofluorescence microscopy showed that UGT1 was distributed throughout
the ER, but interestingly was concentrated in foci near ER exit sites, hinting that the
activity of UGT1 can occur or persist until later maturation steps (Cannon and Helenius,
1999; Arnold et al., 2000). Immunogold microscopy found that although some labeling of
UGT1 was detected in the rough ER, the most intense labeling of UGT1 was in the preGolgi intermediate compartment, with twice as much found as in the rough ER (Zuber et
al., 2001). Glucosidase II and CRT’s presence was also noted in pre-Golgi intermediates.
The presence of the elements of the CNX/CRT cycle in a later ER compartment
reinforces that UGT1 is most active in later steps in the maturation of secretory proteins
(Zuber et al., 2001). Additionally, a proteomic approach relying on fractionation
procedures to separate the rough from the smooth ER determined that UGT1 is present
predominantly in smooth ER microsomes. This result validates partially the notion that
UGT1 is situated deeper in the ER lumen (Gilchrist et al., 2006).
Agreeing with a later involvement of UGT1 in protein maturation, Pearse et al.,
2008, showed that UGT1 reglucosylates proteins only post-translationally. This was
tested by performing a reglucosylation assay on nascent chains arrested on ribosomes
(Pearse et al., 2008). Reglucosylation was only observed when the arrested chains were
released from the ribosomes. The exclusive posttranslational reglucosylation of proteins
could be explained by the localization of UGT1 in a distant ER compartment, supportive
of the previous microscopy and proteomics studies.
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In addition, UGT1 was found in a complex with a number of other ER quality
control proteins, including but not restricted to BiP, PDI and CyB (Meunier et al., 2002).
These data also point to a particular spatial organization of the ER, and suggest that
UGT1 is sequestered in a specific ER location.
Despite these observations, some discrepancies were detected such that other
components of the reglucosylation cycle, CNX and CRT, were excluded from the
complex that contained UGT1 (Meunier et al., 2002), which raises the question of how
the localization of UGT1 relates to its role in the CNX/CRT cycle. Accordingly, further
studies are required to clarify the spatial distribution of UGT1 and how this distribution
affects its function.

The role of UGT1 in physiological processes
UGT1 is essential in mice as knocking out UGT1 is embryonic lethal (Molinari et
al., 2005), and results in activation of ER stress responses (Rutkowski et al., 2006). This
supports that UGT1 plays important physiological roles since its absence had severe
consequences on mice development. However, the activity of UGT1 appears to be
substrate specific, and does not impact equally all maturing proteins. In an investigation
from the Molinari lab, the absence of UGT1 caused either a delay, an acceleration or had
no effect on the maturation of the substrates studied (Solda et al., 2007). The significance
of UGT1 activity is further highlighted by the roles it plays in several physiological
processes including antigen presentation and plant development as shown in the case
studies below.
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UGT1 has been implicated in antigen presentation because in its absence, the
surface expression of the major histocompatibility (MHC) class I molecules is decreased.
In addition, the maturation and peptide loading of MHC class I is defective (Zhang et al.,
2011). Similarly, UGT1 is involved in the maturation of CD1d, the lipid antigen
presentation molecules. In absence of UGT1, CD1d prematurely associates with β2microglobulin (β2-m), and some of these CD1d-β2m heterodimers are unstable.
Interestingly, despite that the levels of CD1d-β2m at the surface were unchanged in
absence of UGT1, the cells exhibited altered antigenicity (Kunte et al., 2013). The
implication of UGT1 in antigen presentation further stresses the importance of studying
its role in other physiological processes. UGT1 recognizes and aids in the folding of
transferrin, which regulates iron levels (Wada et al., 1997), and prosaposin, which is
involved in lysosomal storage diseases (Pearse et al., 2010). Yet, how UGT1 affects
irons levels or lysosomal storage disease progression has never been addressed.
Addressing these questions could make UGT1 a potential therapeutic target.
The Arabidopsis thaliana (A. thaliana) UDP-glucose:glycoprotein
glucosyltransferase, named UGT, also appears to play critical roles in plant physiology.
A recent study showed that UGT is required for the biogenesis of SOBIR I (Suppressor
of BIR 1), which is responsible for the activation of immune responses in A. thaliana
(Zhang et al., 2015). Moreover, UGT has been implicated in the biogenesis of A. thaliana
transmembrane receptors and is essential for the retention of the defective brassinosteroid
receptor bri1-9 in the ER, which is essential for growth. (Jin et al., 2007). These
observations emphasize the importance of UGT in activation of plant immune responses
and plant development.
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In conclusion, it is very clear that UGT1 is an essential factor in various kingdoms
of life, making it crucial to define its detailed mechanism in ER qualify control.

Conclusion
In summary, although we know a great deal about UGT1 from previous studies,
many questions concerning its role and mechanism in ER quality control remain
unanswered. This lack of a complete understanding stems from the adoption of a
reductionist approach that relies on purified components in the assays used to study
UGT1 activity. Studying the activity of UGT1 in the complex environment of the ER
would require more intricately designed approaches. A main hurdle in studying the
mechanism of UGT1 in intact cells is that the product of reglucosylation and that of the
early trimming events by glucosidases I and II are indistinguishable. Moreover, the
spatial organization and compartmentalization of the ER adds another level of
complexity, which cannot be addressed by cell free assays. Our lab has developed a cell
based reglucosylation assay that overcomes this hurdle, and is a powerful tool to advance
our understanding of the reglucosylation or CNX/CRT cycle.
Being such a central and prominent player in the ER quality control, we will pose
and answer, in the next three chapters, fundamental questions concerning the role and
mechanism of UGT1, which can be summarized as follows:
1) What types of substrates are recognized by UGT1 and how does
reglucosylation affect the fate of these substrates?
2) How are reglucosylation-chaperone binding cycles terminated?
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3) Are free thiols recognized as a hallmark of misfoldedness and used as a
handle by UGT1 to retain misfolded substrates in the ER?
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Figure 1.1 Quality control in the ER
Nascent proteins are translocated into the ER via the Sec61 translocon. Glycans are
generally added co-translationally. A set of folding factors such as the Hsp70 BiP, lectin
chaperones and PDIs can assist in the co-translational (co-T) folding of proteins. Some
PDIs directly recognize proteins; others are recruited by lectin chaperones. Additional
folding factors such as peptidyl prolyl isomerases (PPIs) also assist in folding by directly
recognizing proteins or by being recruited by the lectin chaperones. Folding continues
post-translationally (Post-T). A properly folded protein will be targeted to exist out of the
ER via vesicular trafficking to the Golgi. Misfolded proteins are destined for degradation
via the process of ERAD. Early steps of ERAD include recognition of proteins by ERAD
lectins and mannose trimming. Other lectins that recognize mannose-trimmed substrates
target the protein to a retro-translocation complex nucleated by an adaptor protein and
contains BiP, ubiquitin ligases and other factors. Misfolded proteins are retrotranslocated to the cytosol. The AAA ATPase p97 assists in the extraction process.
Proteins are ubiquitinated and degraded by the proteasome.
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Figure 1.2 The glycan code
Glycans are added onto Asn in consensus sites consisting of Asn-X-Ser/Thr. They are
comprised of 2 N-acetylglucosamines, 9 mannoses and 3 glucoses, and are distributed
over the A, B and C branches of the glycan. Early modifications of the glycan
composition in the ER involves sequential trimmings of the first and the second glucoses.
Each of these steps can recruit different ER lectin chaperones. After trimming of the last
glucose, the branch A of the glycan can be reglucosylated by a glucosyltransferase. These
modification steps are usually associated with folding events. Subsequent modifications
involve trimming of mannose residues which could target the protein to exit out of the
ER for vesicular trafficking. More extensive mannose trimming targets the protein for
degradation.
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Figure 1.3 The CNX/CRT cycle
(Tannous et al., 2015b)
The OST complex catalyzes the addition of glycans onto nascent chains (step 1). The first
glucose is trimmed by α-glucosidase I (step 2). Di-glucosylated proteins can bind to
malectin. α-glucosidase II cleaves the second glucose (step 3) forming monoglucosylated glycans, which interact with CNX and CRT. Binding and release from lectin
chaperones could occur (step 4). The second trimming by α-glucosidase II, which
removes the last glucose, triggers the release from the lectin chaperones (step 5). Reglycosylation by UGT1 directs the re-association of the proteins with CNX or CRT (step
6). Properly folded proteins are exported from the ER (step 7). Export from the ER could
involve the binding of substrates to sorting receptors such as ERGIC53 and VIPL.
Glycans of misfolded proteins are further processed by mannosidases (step 8) and
targeted for proteasomal degradation (step 9). The substrate-binding and catalytic
domains of UGT1 are shown with s and c, respectively.
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Figure 1.4 Crystal structure of the calnexin luminal domain. PDB 1JHN
(Schrag et al., 2001)
Calnexin consists of a globular lectin β-sandwich domain from which extends a 140Å
arm domain, also termed the P-domain, which contains repeats of proline rich motifs. In
yellow are shown disulfide bonds. The rest of the structure is disordered and was not
modeled (Schrag et al., 2001).

Figure 1.5 Human UGT1
Human UGT1 has an N-terminal cleavable signal sequence (black rectangle) and a Cterminal REEL ER retention sequence. It appears to be glycosylated at one site, Asn269.
The N-terminal ~80% of UGT1 is composed of the folding sensor domain (light gray),
which contains three thioredoxin-like (Trx) domains predicted from the C. thermophilum
homolog of UGT1, denoted by the green rectangles. The C-terminal domain is the
glucosyltransferase domain (dark gray) where the Asp (D) 1452, Gln (Q) 1453 and Asp
(D) 1454 are essential for the catalytic activity of UGT1.
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CHAPTER 2
REGLUCOSYLATION BY UGT1 DELAYS GLYCOPROTEIN SECRETION
BUT NOT DEGRADATION
(This chapter is adapted from (Tannous et al., 2015a))
Introduction
Misfolded proteins can expose hydrophobic regions that are usually buried in the
folded form. They can also contain unpaired cysteine residues resulting from the failure
to form disulfides. These hallmarks may be recognized by the quality control machinery
to distinguish native from misfolded substrates and to retain misfolded substrates in the
ER and target them for degradation (Ellgaard et al., 1999; Isidoro et al., 1996; Nishikawa
et al., 2005). However, folding intermediates could exhibit similar structural
characteristics to misfolded proteins. Thus, it is more difficult to conceptualize how the
quality control machinery is able to distinguish folding intermediates from misfolded
proteins. Despite that, the ER quality control machinery is able to make that distinction,
thus retaining intermediates in the ER until they attain their native state, and preventing
their premature degradation. Previous work in the literature has proposed that UGT1
could make such a distinction (Tannous et al., 2015b; Tamura et al., 2010; D'Alessio et
al., 2010). Yet, most of these conclusions were drawn from cell free assays, and the
ability of UGT1 to discriminate between foldable intermediates and terminally misfolded
proteins remained an open question.
A pioneering study relied on ER microsomal extracts as the source for UGT1,
and purified native or denatured thyroglobulin as the substrate (Trombetta et al., 1989).
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Interestingly, UGT1 was only able to efficiently recognize denatured thyroglobulin
(Trombetta et al., 1989). While this was the first study showing that UGT1 favors
denatured over native substrates, it is worth stating that thyroglobulin is a large dimer of
660 kDa, containing 14 glycosylation sites and 30 disulfide bonds. The large size, and the
large number of glycans and disulfides could make it difficult to generalize this
mechanism of UGT1 for secretory proteins as most do not possess such complicated
features. Several studies that followed used purified UGT1 from different sources such as
Drosophila, rat liver and S. pombe to study reglucosylation by UGT1. Some of the
substrates investigated were soybean agglutinin, phytohemagglutinin and ribonunclease
B, which are smaller substrates with fewer glycosylation sites and disulfides than
thyroglobulin (Fernandez et al., 1994; Trombetta and Parodi, 1992; Parker et al., 1995).
All these studies agreed that UGT1 preferentially recognized the denatured over the
native form as previously noted with thyroglobulin. Building from these conclusions, one
might hypothesize that UGT1 favors proteins that are deemed misfolded in the ER over
proteins that will ultimately fold. Nevertheless, the affinity of UGT1 to any intermediate
folding states, or to various levels of structural perturbations was not assessed in these
reports. As a result, the hypothesis that UGT1 could favor intermediate folding states of
proteins that will eventually reach the native state could not be excluded.
The abovementioned ribonuclease B (RNase B) substrate was used later more
extensively to determine if purified UGT1 can recognize different levels of substrate
structural perturbations (Trombetta and Helenius, 2000). Cleavage of the last 20 amino
acids of RNase B results in a partially structured state, which UGT1 favored over the
fully denatured or the native state. The study concluded that UGT1 is able to sense
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variations in the level of structural defect (Trombetta and Helenius, 2000). In addition,
exo (1,3)-β-glucanase (β-Glc) was used as another model substrate to further support the
latter observation (Taylor et al., 2004). When the F280S mutation was introduced in βGlc, it caused only a minor loss in β-Glc enzymatic activity, yet reglucosylation by
purified UGT1 increased substantially relative to wild type (Taylor et al., 2004),
corroborating the hypothesis that UGT1 is sensitive to even slight alterations in the
structure of glycoproteins.
Further evidence demonstrating that UGT1 favors near native folding
intermediates came from a study that employed purified UGT1 and fragments of different
lengths and structure of chymotrypsin inhibitor 2 (Caramelo et al., 2003). The fragments
ranged from a short truncation that is fully unstructured, to the native folded full length
protein, and included a longer fragment shown to adopt a near native conformation. The
assay showed that UGT1 preferentially reglucosylated the nearly native long fragment
over the short unstructured fragment or the full length native protein (Caramelo et al.,
2003). Not only did UGT1 distinguish between the various folding states of the
substrates, it appeared to favor late folding intermediates. If these observations were to
be extrapolated to the context of the ER environment, it can be hypothesized that UGT1
favors proteins on the pathway to fold or “on-pathway substrates” and ignores those that
are extensively misfolded or “off-pathway” substrates.
Although the abovementioned studies helped to better delineate the mechanism of
UGT1, they were performed under non-physiological conditions, hence the importance of
studying UGT1 mechanism in live cells. We investigated the ability of UGT1 to
distinguish between “on-pathway” and “off-pathway” glycoproteins and the effect of
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UGT1 reglucosylation on the fate of these proteins in intact cells. We found that UGT1
was able to reglucosylate off-pathway maturation substrates more efficiently and
persistently than wild type maturing secretory pathway clients. Trapping wild type UGT1
substrates in the monoglucosylated state delayed their secretion, whereas trapping offpathway substrates in the monoglucosylated state did not affect their rate of degradation.
This suggested that terminally misfolded substrates were efficiently extracted from the
lectin chaperone binding cycle and targeted for degradation through a dominant process
that was unaffected by the presence of monoglucosylated side chains on the substrate.

Results
The reglucosylation of ERAD substrates
To explore the substrate specificity of UGT1 in live cells, the reglucosylation of model
maturation and quality control substrates was analyzed using a cellular reglucosylation
assay. The MI8-5 Chinese hamster ovary (CHO) cells are deficient in the dolicholpyrophosphate glucose-dependent glycosyltransferase termed Alg6, that is responsible
for glucose transfer during glycan synthesis (Quellhorst et al., 1999). Truncated
unglucosylated N-linked glycans lacking glucoses (Man9GlcNAc2) are transferred instead
of the normal triglucosylated species (Glc3Man9GlcNAc2). Reglucosylation is the sole
mechanism through which glycoproteins can reach the monoglucosylated state in these
cells (Figure 2.1A, bottom scheme). The reglucosylated or monoglucosylated proteins
can be isolated based on their affinity for GST-calreticulin (GST-CRT) (Pearse et al.,
2008; Pearse et al., 2010). Glucosidase inhibition traps reglucosylated glycans in their
monoglucosylated state in MI8-5 CHO cells since these CHO derived cells lack an
28

endomannosidase activity (Karaivanova et al., 1998), further facilitating the ability to
monitor the reglucosylation reaction.
Alpha-1-antitrypsin (A1AT) was chosen as the initial substrate to evaluate for
reglucosylation since it has a number of mutations with varying levels of structural
perturbations and is associated with disease. A1AT is a soluble secretory glycoprotein
synthesized in hepatocytes that belongs to the serine protease inhibitor or serpin family of
proteins. Serpins are monomeric proteins composed of three sheets and nine helices.
Three different variants of A1AT were expressed in MI8-5 cells including wild type and
two mutant variants termed null Hong Kong (NHK) and A1ATZ. NHK is a frame-shift
and premature truncation mutation that is associated with gross misfolding, ER retention
and rapid subsequent turnover by ER-associated degradation (ERAD) (Sifers et al., 1988;
Liu et al., 1999). It was named null as it was found to be absent from serum. A common
pathological variant of A1AT is A1ATZ caused by a single site mutation (E342K)
(Blanco et al., 2006). A1ATZ contains structural perturbations that slow its folding and
favor polymerization (Bottomley, 2011; Kass et al., 2012). While ~15% of A1ATZ is
secreted, the remainder is ER retained and degraded by both ERAD and autophagy
(Lomas et al., 1992; Hidvegi et al., 2010). The retention of polymerized A1ATZ in the
ER of hepatocytes is associated with cirrhosis.
Cells transfected with A1AT were pulsed for 1-hr with [35S]-Met/Cys and either
analyzed directly after the pulse or a 1-hr chase (Figure 2.1B). The pulse and chase were
performed in the presence of the glucosidase inhibitor DNJ to trap reglucosylated
glycans. Cell lines defective in assembling the complete dolichol precursor such as MI8-5
are commonly associated with the hypoglycosylation of nascent proteins since the
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oligosaccharyltransferase frequently transfers the incompletely assembled glycan
inefficiently (Huffaker and Robbins, 1983). The hypoglycosylation of A1AT was
observed for all three forms after immunoprecipitation of the samples with anti-A1AT
sera, resulting in the formation of a ladder of glycosylation states ranging from the faster
migrating unglycosylated protein to the slower migrating fully glycosylated protein
containing all three glycans (Figure 2.1B, lanes 11-16). To confirm that the multiple
bands of A1AT were caused by hypoglycosylation, samples were treated with Peptide Nglycosidase F (PNGase F) to remove any heterogeneity attributed to N-linked
carbohydrates. All protein bands observed collapsed into a single band migrating with the
same mobility as unglycosylated A1AT demonstrating that the different protein bands
resolved were due to different levels of glycosylation (Figure 2.2A, lanes 1-6).
Reglucosylation or the presence of monoglucosylated glycans was probed by
monitoring binding to GST-CRT, a bacterial expressed and purified lectin fusion protein
(Pearse et al., 2008; Pearse et al., 2010). A large number of proteins of a variety of sizes
were found to be monoglucosylated (Figure 2.1B, lanes 1-8). To characterize A1AT
reglucosylation, the GST-CRT pull down was followed by the immunoprecipitation with
anti-A1AT sera (Figure 2.1B, lanes 17-24). Twenty percent of wild type A1AT was
reglucosylated immediately after the pulse and this level diminished to 11% after a 1-hr
chase. Interestingly, the level of reglucosylation doubled for A1AT mutants, NHK and
A1ATZ, and this level of ~40% reglucosylation persisted after 1-hr of chase. These
values were calculated using A1AT possessing all three of its glycans, however similar
reglucosylation efficiencies were obtained when all A1AT glycoforms were grouped. The
fastest migrating protein bands (unglycosylated A1AT) were not recognized by GST30

CRT. Therefore, while all glycoforms of A1AT were reglucosylated, the terminally
misfolded mutant forms were more efficiently reglucosylated than the wild type protein
(See the legend of figure 2.1 for statistical analysis), and the level of reglucosylation of
the two mutant variants was similar even though they possessed different types of
abnormalities.
To determine if UGT1 efficiently modified other ERAD or disease-associated
substrates, the reglucosylation of several additional proteins was studied. These included
proteins with varying topologies such as the soluble α-N-acetylgalactosaminidase (αNAGAL), as well as two membrane proteins, T-cell receptor alpha-subunit (TCRα) and
tyrosinase.
α-NAGAL is a lysosomal protein that possesses five N-linked glycans (Clark and
Garman, 2009). There are a number of loss-of-function mutations in α-NAGAL that are
associated with Schindler/Kanzaki disease (Clark et al., 2012). The reglucosylation of Cterminally tagged FLAG constructs of wild type α-NAGAL and the missense E367K
mutant was studied as described above. Samples were treated with Endoglycosidase H
(EndoH) to differentiate EndoH sensitive ER glycoforms of α-NAGAL from protein that
had trafficked through the Golgi and received complex sugars rendering them EndoH
resistant. During the timeframe studied, all forms of α-NAGAL appeared to be EndoH
sensitive consistent with their ER residency. The level of reglucosylation for wild type
protein (7%) was lower than that observed for the E367K mutant (10%), immediately
after the pulse (Figure 2.1C). This trend continued after the 1-hr chase, where WT αNAGAL reglucosylation was 10% and the mutant was 15%. While the difference
between reglucosylation levels of the WT and the mutant α-NAGAL was not statistically
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significant at the 0-hr time point, it was after 1-hr of chase (See the legend of figure 2.1
for statistical analysis). Therefore, the α-NAGAL E367K mutant was more efficiently
modified compared to the wild type protein after 1-hr of chase.
TCRα is a membrane glycoprotein that forms a larger heterocomplex in T
lymphocytes, however when it is unable to assemble, it is rapidly degraded through the
ERAD pathway (Bonifacino et al., 1990; Huppa and Ploegh, 1997; Call et al., 2002).
MI8-5 cells were transfected with a TCRα construct containing a C-terminal HA tag and
pulsed for 1-hr in [35S]-Met/Cys followed by a chase for the indicated times in the
presence of a glucosidase inhibitor. TCRα was found to be efficiently (23-25%) and
persistently reglucosylated regardless of the duration of the chase period (Figure 2.1D).
Tyrosinase is a type I membrane glycoprotein with seven N-glycans that is
involved in melanin biosynthesis (Ujvari et al., 2001). A C89R missense mutation for
tyrosinase is an ERAD substrate and this loss-of-function mutation is associated with
albinism (Halaban et al., 1997). MI8-5 cells were transfected with C-terminal FLAG
constructs of either human wild type tyrosinase or a C89R mutant, and a pulse-chase
procedure was performed as described above. Both wild type and the C89R mutant of
tyrosinase were efficiently reglucosylated, with only a very slight increase in the level for
reglucosylation observed for C89R over wild type immediately after 1-hr of chase
(Figure 2.1E).
MI8-5 cells supported the efficient glycosylation and reglucosylation of a variety
of glycoproteins. Three of four glycoproteins studied were efficiently glycosylated while
a fourth protein (A1AT) was found to be hypoglycosylated, indicating that
hypoglycosylation of glycoproteins in the MI8-5 cells was protein dependent. All four
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proteins were efficiently reglucosylated. The level for reglucosylation for the two mutants
of A1AT was doubled that observed for wild type A1AT. Wild type α-NAGAL and
tyrosinase were efficiently reglucosylated, but the reglucosylation of their mutants was
associated with only a modest increase in modification, and in the case if tyrosinase it
was seen only after a 1-hr chase.

Trapping proteins in their monoglucosylated state delays their secretion
Reglucosylation of proteins by UGT1 supports their rebinding to the lectin chaperones
CNX and CRT (Caramelo and Parodi, 2008). To determine if trapping glycoproteins in
their monoglucosylated state would affect their secretion, a pulse chase experiment was
performed using MI8-5 cells transfected with wild type A1AT in the absence and
presence of DNJ. Cell lysates and the culture media were collected and analyzed.
The ability of glucosidase inhibition to trap wild type A1AT in a
monoglucosylated state was verified, as the addition of DNJ greatly increased the level of
reglucosylation observed with the lysate samples after sequential precipitation with GSTCRT and anti-A1AT sera (Figure 2.2A, compare lanes 7-9 to 25-27). Trapping A1AT in
the monoglucosylated state was also associated with a significant decrease in secretion,
as less than half the amount of A1AT was found in the culture media after a 2-hr chase
when DNJ was present compared to in its absence (Figure 2.2A compare lanes 10-12 to
28-30, and Figure 2.2C). The secreted protein found in the media was largely not
glucosylated as probed by GST-CRT binding (Figure 2.2A, lanes 16-18 and 34-36).
These results demonstrated that the inhibition of deglucosylation of reglucosylated
protein delayed the secretion of ectopically expressed wild type A1AT.
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Since quality control pathways can be saturated by protein overexpression, the
effect of trapping a reglucosylated substrate on the secretion of an endogenous UGT1
substrate was analyzed. Previously, we found that prosaposin was an obligate substrate
for UGT1 as it was efficiently reglucosylated in MI8-5 cells and its maturation was
inefficient in ugt1-/- mouse embryonic fibroblast cells (Pearse et al., 2010). As previously
observed, glucosidase inhibition trapped a significant fraction of the prosaposin in the
monoglucosylated state (Figure 2.2B, lanes 13-15). Furthermore, glucosidase inhibition
and monoglucosylation trapping was associated with less than half the amount of
prosaposin being secreted into the culture media after 2-hr of chase (Figures 2.2B, lanes 9
and 18, and 2C). The delay in secretion of prosaposin in the presence of DNJ appeared to
be due to CRT and CNX binding to prosaposin as chaperone binding levels increased in
the presence of the glucosidase inhibitor (Figure 2.2D, compare lanes 3 to 6, and 21 to
24). Altogether, these results demonstrated that trapping either ectopically expressed wild
type A1AT or endogenously expressed prosaposin in the monoglucosylated state
significantly inhibited their secretion.

Trapping ERAD substrates in their monoglucosylated state does not delay their
turnover
Next, we determined if trapping an efficiently reglucosylated ERAD substrate in the
monoglucosylated state would influence its turnover. First, the reglucosylation and
secretion of NHK was followed in MI8-5 cells in the absence and presence of DNJ by
pulse-chase analysis. NHK was not secreted regardless of whether DNJ was excluded or
included in the pulse and chase conditions, demonstrating the effectiveness of the quality
control process in retaining and degrading this terminally misfolded protein and
34

recapitulating the null phenotype (Figure 2.3A, lanes 9-12 and 29-32). A fraction of NHK
was also observed in the Triton X-100 insoluble material (Figure 2.3A, lanes 13-16 and
33-36). This fraction was included in the quantification of the amount of NHK remaining
before and after trapping in the monoglucosylated state. Glucosidase inhibition efficiently
captured NHK in the monoglucosylated state as observed by sequential pull-downs with
GST-CRT and anti-A1AT sera (Figure 2.3A, compare lanes 25-28 to 5-8). Interestingly,
trapping NHK in the monoglucosylated glycoforms did not influence the half-life of
NHK regardless of the conditions employed (Figure 2.3B). Monoglucosylated NHK was
detected in the detergent insoluble fraction even after 6-hr of chase indicating that
insoluble NHK was also reglucosylated (Figure 2.3A, lanes 37-40). Yet, it is not clear if
reglucosylation of insoluble NHK occurred before or after the accumulation of NHK in
aggregates. The increase in NHK levels observed after the addition of proteasome
(MG132) or the mannosidase (kifunensine) inhibitors, demonstrated that NHK continued
to be degraded by ERAD in the absence or presence of glucosidase inhibition (Figure
2.3C and D).
To test the generality of this result, we investigated whether trapping another
ERAD substrate, TCRα, in the monoglucosylated state would affect its disposal by
ERAD. Persistent monoglucosylation of TCRα was observed in the presence of the
glucosidase inhibitor as observed by the pull-down with GST-CRT followed by
immunoprecipitation with anti-HA serum (Figure 2.4A, compare lanes 13-16 to 5-8). The
half-life of TCRα was not significantly affected by the presence of the glucosidase
inhibitor, as the half-life of TCRα was ~1 hr in the absence or the presence of DNJ
(Figure 2.4B). TCRα was not detected in the Triton X-100 insoluble material (data not
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shown), indicating that TCRα analyzed using the detergent soluble fraction was
representative of the total amount of the protein remaining. TCRα was degraded by
ERAD as MG132 inhibited its turnover; however, mannosidase inhibition stabilization
was less efficient (Figure 2.4C and D). Altogether, these results demonstrated that the
degradation of the ERAD substrates NHK and TCRα was unaffected by being trapped in
the monoglucosylated state.

The timing and persistency of reglucosylation
The previous experimental strategy trapped reglucosylated substrates in their
monoglucosylated state to query the influence on secretion or degradation. Since the
persistent trap did not allow the determination of the timing for reglucosylation, a
transient 15 min window of glucosidase inhibition was applied at various time points in
respect to the radioactive pulse and the cold chase to trap reglucosylated substrates over a
range of times. Reglucosylated substrates were isolated using GST-CRT followed by the
immunoprecipitation of the specific substrate.
After maturing properly in the ER, prosaposin has two separate fates: it can traffic
to lysosomes where it is processed by cathepsin D into four separate proteins that act as
co-factors for different lipid hydrolases, or it can be secreted as a full-length protein with
only its signal sequence removed (O'Brien et al., 1994; Lefrancois et al., 2003). To
differentiate ER resident prosaposin in cell lysates from lysosomal prosaposin,
prosaposin immunoprecipitated from cell lysates was treated with EndoH. High-mannose
glycoforms consistent with ER residency remain EndoH sensitive, while complex sugar
glycoforms that have trafficked through the Golgi become EndoH resistant (Halaban et
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al., 1997). Most of the prosaposin from cell lysates displayed an EndoH sensitive profile
throughout the experiment, however after 15 min of chase a fraction of prosaposin that
increased slightly with time was found to be EndoH resistant (Figure 2.5A, lanes 6 and
8).
The reglucosylation of prosaposin was transient as monoglucosylated protein was
isolated by GST-CRT most effectively when DNJ was added during the 15 min pulse
(Figure 2.5A, lanes 17 and 18, and Figure 2.5B). The amount of prosaposin trapped in the
monoglucosylated state with the 15 min of DNJ treatment greatly decreased during the
chase even though a significant fraction of prosaposin continued to be EndoH sensitive
signifying ER residence. A similar profile was observed for transiently expressed wild
type A1AT (Figure 2.5C and D). Monoglucosylated A1AT was generated only during the
15 min pulse period and did not accumulate after a chase period of 15 min or more.
In contrast, reglucosylation of the ERAD substrate NHK A1AT was more
efficient during the pulse period and reglucosylation persisted for the next hour (Figure
2.5C and D). After 105 min of chase, the reglucosylation level dropped to roughly a third
of its maximum. While the triton-insoluble fraction with wild type A1AT remained
empty throughout the chase period, the triton-insoluble fraction for NHK increased in a
time dependent fashion. The persistent reglucosylation of NHK appeared to contribute to
its ER retention and the lack of appearance in the media to create the null phenotype.
Overall, these results indicated that for both prosaposin and wild type A1AT,
reglucosylation occurred early in the maturation process. Though protein remained in the
ER during the extended chase period, it did not appear to be monoglucosylated. For the
A1AT NHK mutant variant, reglucosylation occurred at a higher level and persisted,
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consistent with the conclusion that UGT1 reglucosylates off-pathway aberrant structures
most efficiently.

Efficient reglucosylation of reduced protein
Some of the previous results have suggested that UGT1 does not modify grossly
misfolded proteins. This was in part supported by the observation that in some cases ER
glucosyltransfearses did not recognize reduced substrates (Pearse et al., 2008; Fernandez
et al., 1998; Ritter and Helenius, 2000). The timing of DTT addition, its activation of the
UPR and the employment of different species complicate the interpretation of these
results (Travers et al., 2000). We determined if DTT affected the reglucosylation of the
obligate UGT1 substrate prosaposin using our cell-based reglucosylation assay. Cells
were pulsed with [35S]-Met/Cys for 30 min in the presence or absence of DTT and either
processed immediately after the pulse or after an oxidative chase for 1 hr. DNJ was added
to trap reglucosylated substrates and the samples were processed by immunoprecipitation
and using GST-CRT pull downs.
Reduced prosaposin migrated more slowly than prosaposin that accumulated
under oxidizing conditions as free thiols were modified by the alkylating agent N-ethyl
maleimide included in the lysis buffer (Figure 2.6A, lanes 1-4). The amount of
prosaposin was also diminished by DTT treatment likely due to the activation of UPR
and translation attenuation. Maximal reglucosylation of prosaposin was observed
immediately after the pulse when glucosidases were inhibited by DNJ (Figure 2.6A, lane
10 and 2.6B), and this level dropped significantly after a 1-hr oxidative chase (Figure
2.6A, lane 30 and 6B). Optimal reglucosylation also occurred in the presence of DTT
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immediately after the pulse (Figure 2.6A, lane 12 and 2.6B), but this level of
reglucosylation remained elevated even after the chase. When oxidation was initiated
post-translationally, prosaposin was more efficiently reglucosylated compared to
commencing oxidation during translation. This suggested that the post-translation
oxidation of prosaposin was not as efficient and created aberrant conformations that
continued to be recognized by UGT1 even after 1 hr of oxidation. Therefore, optimal
reglucosylation occurred immediately after the pulse regardless of whether DTT was
present; however, DTT supported efficient and persistent reglucosylation consistent with
UGT1 preference for non-native substrates.

Discussion
A main question concerning the biological role of UGT1 as a central decision
maker in the fate of glycoproteins in the ER is whether UGT1 is able to recognize
productively folding immature and/or terminally misfolded proteins, and how it affects
the subsequent cellular fates of the proteins it modifies. Using a cell based
reglucosylation assay, we found that UGT1 generally glucosylated mutant, off-pathway
substrates more efficiently than wild type substrates. Secretion of wild type substrates
was slowed and less efficient when they were trapped in the monoglucosylated state.
Surprisingly, the turnover of off-pathway substrates was not affected by locking them in
monoglucosylated states. These results suggested that UGT1 was capable of
differentiating between native and non-native proteins, but downstream factors appeared
to play a dominant role in determining the fate of terminally misfolded proteins.
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The initial studies using cell-free or purified protein assays showed that UGT1
favored the modification of non-native compared to native conformations (Trombetta et
al., 1989; Fernandez et al., 1994; Trombetta and Parodi, 1992; Parker et al., 1995; Sousa
et al., 1992). More recent and detailed studies using biophysically characterized and
engineered substrates further examined the specificity of UGT1 and found the
preferential reglucosylation of proteins that are partially structured or possessed minor
local folding defects (Taylor et al., 2004; Trombetta and Helenius, 2000; Caramelo et al.,
2003; Ritter and Helenius, 2000; Caramelo et al., 2004; Ritter et al., 2005). In some of
these reports, grossly misfolded structures were poorly modified. The glucosylation of
biophysically characterized neoglycoproteins derived from C-terminal truncation
fragments of chymotrypsin inhibitor 2 showed that UGT1 had a preference for fragments
with molten globule-like conformations when compared to random coil or native
conformations (Caramelo et al., 2003; Caramelo et al., 2004). Consistent with the
preference of ER glucosyltransferases for near native targets, in some cases they did not
efficiently modify reduced proteins (Pearse et al., 2008; Fernandez et al., 1998; Ritter and
Helenius, 2000). The reglucosylation of cruzipain in Trypanosoma cruzi was directed
towards later oxidative intermediates that enabled binding by its lone lectin chaperone
calreticulin (Labriola et al., 1999). An earlier study using MI8-5 cells found that late but
not early oxidative intermediates of hemagglutinin were reglucosylated on membrane
proximal glycans, which supported persistent CNX binding (Pearse et al., 2008). From
these results, it was concluded that UGT1 recognizes near native substrates more
efficiently than native or severely misfolded substrates. This suggested that UGT1 might
possess the ability to redirect the binding of lectin chaperones to maturing substrates that
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are expected to be salvageable for eventual proper on-pathway folding and trafficking
(D'Alessio et al., 2010).
Our cellular results are indicative of a less discriminatory role for UGT1 in live
cells as UGT1 generally reglucosylated terminally misfolded mutant proteins more
efficiently than immature wild type proteins. UGT1 was capable of modifying both onpathway and off-pathway targets. The Z-variant involves a missense mutation and selfassociates to form ER-retained polymers (Lomas et al., 1992). The less common NHK
mutation consists of a frame-shift at position Leu318 that creates a premature termination
codon at position 334 producing a more severe disruption to A1AT (Sifers et al., 1988).
NHK is ER retained and subsequently degraded by ERAD. As A1AT is comprised of 3
sheets and 9 helices, NHK is missing or has mutations in one or two of the strands from
each of the three sheets. Though Z and NHK likely have very different levels of structural
perturbations, they are both reglucosylated at approximately twice that observed for wild
type A1AT indicative of the ability of UGT1 to recognize terminally misfolded
substrates. Ferris et al., found that the level of mutant A1AT in triton-insoluble fractions
was increased in MEF cells lacking UGT1 suggestive of a role for UGT1 in maintaining
the solubility for glycoproteins (Ferris et al., 2013). However, in our study reglucosylated
mutant A1AT was also found in the triton-insoluble fractions suggesting that
reglucosylation did not ablate aggregation. These differences might be due to the
hypoglycosylation or the constitutive activation of UPR found in MI8-5 cells (Pearse et
al., 2008). Although UPR is activated in MI8-5 cells, the total levels of UGT1, CNX,
CRT and BiP are unchanged (Pearse et al., 2008), which suggests that any difference, if
existent, in their role in ER quality of MI8 compared to WT CHO cells, is not due to
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changes in their abundance. Whether the activation of UPR has other side effects remains
unknown. The hypoglycosylation does not seem to affect the fate of the protein. When
fully glycosylated and hypoglycosylated A1AT were quantified (data not shown), similar
trends in the extent of reglucosylation, secretion and degradation were observed. Yet, it
remains to be determined if hypoglycosylation could have other consequences that have
not been addressed yet, such as its effect on protein solubility or impact on interaction of
the substrates with the lectin chaperones.
The ERAD substrate TCRα was also efficiently reglucosylated, as were the
disease associated mutants for α-NAGAL and tyrosinase. However, the increase in the
reglucosylation of the mutant for α-NAGAL compared to its wild type counterpart was
not as high in magnitude as was observed for A1AT, and no increase in reglucosylation
was observed for the mutant of tyrosinase compared to wild type. The reglucosylation
assay traps reglucosylated glycans after a single reglucosylation event. Therefore, it
cannot differentiate between the reglucosylation of folding intermediates that are
transiently glucosylated from a terminally misfolded protein that might be persistently
reglucosylated. Wild type tyrosinase appears to be a slow and inefficient folder (Halaban
et al., 1997). α-NAGAL also appears to fold inefficiently in CHO cells. This likely also
helps to favor the efficient modification of their wild type proteins, dampening the
difference in reglucosylation between wild type and mutants. Maturation of these difficult
folders maybe further derailed in MI8-5 cells since the transfer of Man9GlcNAc2 glycans
bypasses the initial binding to CNX and CRT initiated by glucosidases I and II trimming
of the triglucosylated glycan. Lectin chaperone binding is solely directed by UGT1
reglucosylation in MI8-5 cells (Figures 2.1A and 2.7A).
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Earlier studies using a CHO-derived cell line that transfers Man5GlcNAc2
carbohydrates (MadIA214 cells) found that maturing HA was reglucosylated, as well as a
mutant of ribophorin that is an ERAD substrate (Ermonval et al., 2000; Ermonval et al.,
2001). The fate of trapped monoglucosylated proteins was not followed and the
efficiency for the reglucosylation of the mutant of ribophorin was not compared to the
native ER resident protein. These studies displayed the scope of proteins modified by the
glucosyltransferase in live cells and that proteins possessing Man5 side chains are
suitable substrates for modification. As mannosidase inhibitors stabilized mutant
ribophorin expressed in MadIA214 cells that lacked B and C branch mannose residues,
these results also suggest that mannose trimming of the A-branch might be required for
ERAD. Alternatively, these mannose derivatives might also inhibit the binding of ERAD
factors to the downstream ERAD adapter SEL1L, as has been found for EDEM1,
EDEM3 and OS-9 (Christianson et al., 2008; Cormier et al., 2009; Saeed et al., 2011).
Proteomic and morphological studies indicated that UGT1 is largely situated in
the smooth ER near ER-exit sites (Zuber et al., 2001; Gilchrist et al., 2006). This
positioning is consistent with the observation that reglucosylation occurs posttranslationally after the nascent chain has been released from the ribosome-associated
translocon as ribosome-arrested nascent chains were unable to be reglucosylated (Pearse
et al., 2008). This provides an explanation for the observation that UGT1 displayed a
preference for late oxidative intermediates or folding domains in MI8-5 CHO cells and T.
cruzi for influenza hemagglutinin and cruzipain, respectively (Pearse et al., 2008;
Labriola et al., 1999). Therefore, the localization and accessibility of the enzyme rather
than an inherent specificity towards more mature substrates likely explain these findings.
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Conflicting results have been obtained for the ability of UGT to modify reduced
proteins. Several studies found that UGT did not modify reduced proteins favoring the
conclusion that UGT does not recognize grossly misfolded substrates (Pearse et al., 2008;
Trombetta and Helenius, 2000; Fernandez et al., 1998; Ritter and Helenius, 2000). In
some instances, reglucosylation was dependent on the alkylating agent employed
(Trombetta and Helenius, 2000) while in other cases, UGT1 was found to modify
reduced proteins (Taylor et al., 2004; Zapun et al., 1997). The absence of reglucosylation
in microsomes or cells treated with DTT could be explained by either the timing being
soon after synthesis as reglucosylation appears to occur post-translationally, or perhaps
problems with the protein bookkeeping in cells as DTT induces the UPR that leads to
protein translation attenuation. We found that DTT supported the efficient and persistent
reglucosylation of endogenous prosaposin in cells, favoring the conclusion that UGT1
can modify severely misfolded non-native substrates.
UGT1 can also recognize slight structural perturbations as it efficiently modified
the orphan subunit of the heteromeric T-cell receptor, TCRα. A recent study found that
unassembled TCRα caused the release of its single transmembrane region into the ER
lumen where it was then targeted for ERAD (Feige and Hendershot, 2013). The ability of
UGT1 to recognize slight alterations is also exploited for the regulation of cellular
processes such as antigen presentation and calcium homeostasis by supporting the
recruitment of lectin chaperones and their associated oxidoreductase ERp57 (Kunte et al.,
2013; Camacho and Lechleiter, 1995; John et al., 1998; Li and Camacho, 2004). The
reglucosylation of fully folded MHC class I heavy chain or SERCA2b modulates their
function and localization. It is clear that UGT1 can recognize subtle aberrations in protein
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structure but it also efficiently recognizes terminally misfolded substrates. UGT1 does
not appear to have the ability to preferentially select on-pathway or repairable substrates
for further lectin chaperone intervention but rather simply modified non-native substrates.
The secretion of glucosylated trapped wild type proteins was significantly
delayed. A similar finding was previously observed for endogenous cruzipain in T. cruzi
that naturally transfers high mannose glycans (Labriola et al., 1995). That secretion of
wild type glucosylated proteins in cells treated with DNJ would ultimately saturate at the
same level of proteins secreted in cells non-treated with DNJ remains to be investigated.
This can be done by examining secretion in both conditions at longer time points. In
sharp contrast, the more efficient reglucosylation of ERAD substrates did not appear to
influence their fate, or the turnover of terminally misfolded proteins when glucosylated
glycans were trapped on the substrate. This was suggestive of a dominant downstream
ERAD sorting receptor playing an important role that was unaffected by the presence of
glucosylated glycans or lectin chaperone binding. Mannose trimming exposes α1,6-linked
mannoses side chains on C-chains that act as degradation tags for recognition by the
luminal ERAD receptors (Quan et al., 2008; Clerc et al., 2009). Alternatively, A-branch
demannosylation would remove a glycoprotein from being a substrate for reglucosylation
and subsequent lectin chaperone binding to possibly favor recognition by ERAD
machiner (Olivari et al., 2006).
Therefore, mannose trimming likely plays a key role in rapidly sorting the trapped
glucosylated proteins for destruction. Understanding the precise mechanism by which
mannose trimming contributes to the ERAD process is complicated by the dual role that
N-linked glycans play in the secretory pathway as they act as sorting and quality control
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tags, as well as docking tags for ER machinery complex formation and targeting (Hebert
and Molinari, 2012).
The recognition and modification of ERAD substrates by UGT1 appears to be
more a consequence of the ability of UGT1 to recognize structural imperfections akin to
molecular chaperones rather than of functional significance that directly impacts the fate
for defective proteins. Downstream ERAD receptors evidently efficiently sort defective
cargo for destruction regardless of their glucosylation status. Our results favor the model
that UGT1 modifies non-native proteins regardless of whether they are on- or offpathway (Figure 2.7A and 2.7B). This query likely occurs after an initial period of
maturation that is dictated by the localization of UGT1 and its access to the maturing
nascent chain. Importantly, reglucosylation inhibits secretion of on-pathway substrates
either by supporting persistent chaperone binding or inhibiting binding to anterograde
targeting receptors (Wieland et al., 1987; Balch et al., 1994; Aridor and Balch, 1996).
The significance of the more efficient reglucosylation of off-pathway terminally
misfolded substrates is uncertain as they evidently display a signal that is efficiently
recognized by a downstream ERAD receptor. Perhaps persistent lectin chaperone binding
of the monoglucosylated substrate localizes the ERAD substrate to a location in the ER
where ERAD receptors or mannosidases are concentrated such as the proposed ER
quality control compartment (ERQC) where CNX, CRT, ER ManI and EDEM1 have
been localized but not UGT1 and ERp57 (Avezov et al., 2008). Likely candidates to
shepherd glycosylated proteins through this retrograde trafficking route include ER
ManI/Man1B1, EDEM1-3, Os-9 and XTP3-B (Hosokawa et al., 2003; Molinari et al.,
2003; Oda et al., 2003; Hosokawa et al., 2009; Groisman et al., 2011; Aikawa et al.,
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2014). Currently there is vigorous debate over the location, roles and substrate selectivity
for some of these factors.
Some diseases are caused by the ER retention of an otherwise active protein by an
apparent overzealous quality control process (Guerriero and Brodsky, 2012), which is
capable of recognizing slight imperfections found even associated with active proteins. If
the quality control process could be relaxed for these substrates, proper trafficking could
alleviate the loss-of-function disease. UGT1 is a prime candidate for modulation for
diseases of this category as the reglucosylation of wild type on-pathway targets supported
ER retention, and delayed the secretion of potentially active substrates. The fact that the
terminally misfolded substrates were still cleared efficiently and rapidly when proteins
were trapped with monoglucosylated glycans suggests that the modulation of the activity
of UGT1 might not disrupt the ERAD process and might provide an effective therapy for
the treatment of some of these loss-of-function diseases. A recent study showed that
recombinant ER ManI/Man1B1 was capable of trimming glucosylated glycans, and
favored the trimming of denatured proteins (Aikawa et al., 2014); however, there is
current debate on whether this exo-mannosidase is localized to the ER or Golgi, and the
necessity of its activity for ERAD (Avezov et al., 2008; Pan et al., 2013; Ninagawa et al.,
2014). Further studies will be required to identify the mechanism by which
reglucosylated ERAD substrates are efficiently recognized and targeted for degradation.
Sorting out these concerns and the mechanism by which reglucosylated ERAD substrates
are efficiently recognized and targeted for degradation will require further cellular
experiments, as well as approaches using purified components. However, in the next
chapter, we will discuss how mannose trimming is involved in termination of
47

reglucosylation cycles, and potentially mannosidases could be extracting proteins from
the CNX cycle for degradation.

Materials and Methods
Reagents- MI8-5 Chinese hamster ovary (CHO) cells were a gift from S. Krag (Johns
Hopkins University, Baltimore, MD) (Quellhorst et al., 1999). Plasmids for pGEX-3X
GST-calreticulin, T cell receptor α (TCRα) with a HA tag at its C terminus, human α1antitrypsin and α-NAGAL were from M. Michalak (University of Alberta), S. Fang
(University of Maryland), M. Ziak and J. Roth (University of Zurich), and S. Garman
(University of Massachusetts, Amherst), respectively. Polyclonal rabbit α1-antitrypsin
(Dako, Denmark) and calreticulin antisera (Thermo Fisher Scientific), monoclonal mouse
HA antibodies (Roche, Mannheim, Germany) and polyclonal goat antisera against murine
prosaposin (G. Grabowski, University of Cincinnati, College of Medicine) were obtained
as indicated. Cell culture material and Lipofectamine 2000 were purchased from
Invitrogen (Carlsbad, CA) and polyethylenimine (PEI) from Polysciences Inc.
(Warrington, PA). [35S]-Met/Cys was acquired from PerkinElmer (Waltham, MA).
Reduced glutathione Sepharose 4B and protein- A Sepharose 4B were from GE
Healthcare (Uppsala, Sweden) and protein G-plus agarose beads from Santa-Cruz
Biotechnology (Santa Cruz, CA). N-butyl deoxynojirimicin (DNJ) and kifunensine (KIF)
were obtained from Toronto Research Chemicals (Toronto, Canada). PNGase F and
EndoH were acquired from New England Biolabs (Ipswich, MA). All other reagents were
purchased from Sigma-Aldrich.
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Transfection and metabolic labeling- MI8-5 CHO cells were cultured in minimum
essential media alpha supplemented with 5 or 10% fetal bovine serum (FBS), 100 U/ml
penicillin and 100 mg/ml streptomycin at 34 °C in 5% CO2. Nearly confluent cells were
transfected with the indicated plasmid using Lipofectamine 2000 or polyethyleneimine
according to manufacturer’s instructions.
Cells were starved for 30 min or 1 hr in Cys/Met free media with 0.5 mM DNJ
where indicated, then pulse labeled with 60 µCi of [35S]-Cys/Met in 3.5 cm plates for 30
min or 1 hr as indicated. When analyzing degradation of TCRα or NHK, no prior amino
acid starvation was performed. Instead, cells were pre-incubated with 0.5 mM DNJ for 30
min before pulse labeling. Immediately after the pulse, cells were washed with phosphate
buffer solution (PBS; 137 mM NaCl, 2.7 mM KCl, 4.3 mM Na2HPO 4, and 1.4 mM
KH2PO4) and chased with regular growth media for the indicated times. DNJ was present
throughout the chase where indicated except for figure 2.5 where DNJ was added at the
indicated times relative to the start of chase. Radiolabeled cells were washed twice with
PBS on ice followed by lysis with MNT buffer (20 mM 2-(N-morpholino) ethanesulfonic
acid (MES), 100 mM NaCl, 0.5% triton X-100, 30 mM Tris-HCl pH 7.5) containing 50
µM calpain inhibitor I, 1 µM pepstatin, 10 µg/mL aprotinin, 10 µg/ml leupeptin, 0.4 mM
phenylmethyl-sulfonyl fluoride (PMSF) and 20 mM N-ethyl maleimide (NEM). Media
and the triton X-100 insoluble pellet were collected where indicated. Cells were
incubated as designated with 20 µM MG132 or 100 µM KIF for 4 or 2 hr before the
pulse, respectively.
Immunoprecipitations and SDS-PAGE- The post-nuclear fraction was pre-cleared
with 10% zysorbin for 1 hr at 4 °C then incubated with antibody and protein A-sepharose
49

beads and rotated end-over-end for 14 hr at 4 °C, except with the prosaposin antibody
where protein G-agarose was used. The triton X-100 insoluble pellet was solubilized in
1% SDS in 100 mM Tris-HCl pH 8 by high-speed vortexing at 22 °C for 5 min, followed
by heating for 10 min at 100 °C then sonication. The SDS was quenched by dilution with
excess MNT buffer. The media and triton X-100 insoluble fractions were also pre-cleared
with 10% zysorbin and immunoprecipitations were conducted as described above for the
post-nuclear supernatant. Immunopellets were washed with 100 mM Tris pH 8.6, 300
mM NaCl, 0.1% SDS and 0.05% triton X-100. Proteins were eluted from beads with
reducing sample buffer then SDS-PAGE was performed. Radiolabeled samples were
visualized by phosphorimaging (FLA-500; Fujifilm) and quantified using MultiGauge
software or ImageQuant (Fujifilm).
GST-calreticulin pull-down- Recombinant GST-calreticulin was expressed in E. coli
and puriﬁed as previously described (Pearse et al., 2008; Baksh and Michalak, 1991). A
fraction of the cell lysate was incubated with 8 µg of purified GST-calreticulin pre-bound
to reduced glutathione beads at 4 °C and rotated end-over-end for 14 hr. Samples were
washed with 100 mM Tris pH 8.6, 300 mM NaCl, 0.1% SDS and 0.05% triton X-100,
and eluted with reducing sample buffer. If followed by immunoprecipitation, samples
were eluted with 1% SDS in 10 mM Tris pH 7.5 and 150 mM NaCl at 100 °C and
quenched with excess MNT buffer followed by incubation with the corresponding
antisera and sepharose beads overnight and washing as described above.
Co-immunoprecipitation studies with calnexin and calreticulin- Cells were grown in
10 cm plates, lysed with 2% CHAPS in 50 mM HEPES, 200 mM NaCl pH 7.5 (HBS)
and incubated with the respective antibody for 3 hr. Immunopellets were washed with
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0.5% CHAPS in HBS and eluted from beads with reducing sample buffer. When
followed by a second immunoprecipitation, samples were eluted with 1% SDS in 10 mM
Tris pH 7.5, 150 mM NaCl at 100 °C, quenched with excess 2% CHAPS in HBS
followed by incubation with the corresponding antisera and sepharose beads overnight
and washing with 0.5% CHAPS in HBS.
Calculation of percentages of reglucosylation- The percentage of reglucosylation was
calculated by dividing the number obtained from quantifying the bands in the lanes with
the GST-CRT pull down followed by immunoprecipitation, by the number obtained from
quantifying the bands in the lanes with the corresponding immunoprecipitation directed
against the given substrate. A larger fraction of the cell lysate was used for the GST-CRT
pull down followed by immunoprecipitation. Since different percentages of lysate were
used to perform the GST-CRT pull down followed by immunoprecipitation and the
immunoprecipitation alone, this number was accounted for in the division. A linear
correlation is assumed between the signal and the fraction of cell lysate used. Yet, due to
an expected partial loss of signal as a consequence of multiple washes, the actual
percentages of reglucosylation may be higher. The fully glycosylated bands were used for
the quantification when they were well resolved. Otherwise, all bands were quantified.
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Figure 2.1 Reglucosylation of ERAD and disease associated mutants is efficient.
(A) Schematic of glycan processing in MI8-5 and wild type cells. While wild type cells
allow the transfer of triglucosylated glycans onto the nascent chain, unglucosylated
glycans are transferred in MI8-5 cells. Thus, monoglucosylated glycans can only be
generated through reglucosylation by UGT1 in MI8-5 cells. G, glucose; GlsI, glucosidase
I; and GlsII, glucosidase II. (B) Right- MI8-5 CHO cells were transiently transfected
either with an empty vector (mock) or with wild type alpha-1-antitryspin (WT A1AT),
alpha-1-antitrypsin null Hong Kong (NHK) and alpha-1-antitrypsin Z (A1ATZ). Cells
were radiolabeled for 1 hr and chased for the indicated times. 0.5 mM DNJ was added to
the pulse and chase media. Monoglucosylated proteins were isolated by GST-calreticulin
(CRT) pull down from 10% of the cell lysate each and WT A1AT, NHK and A1ATZ
were isolated with A1AT antisera. Monoglucosylated WT A1AT, NHK and A1ATZ
were isolated by GST-CRT pull down followed by immunoprecipitation with A1AT
antisera from 80% of the cell lysate. All samples were resolved on 9% SDS-PAGE
reducing gels. The numbers next to the bands indicate the number of glycans on A1AT.
The asterisk indicates the previously identified endogenous UGT1 substrate prosaposin.
Left- Quantification of the percentage of reglucosylation of WT A1AT, NHK, and
A1ATZ. The quantifications of the fully glycosylated (top band) from lanes 19-24 were
divided by the quantifications from lanes 11-16 that were multiplied by 8 to account for
lower percentage of sample used. The error bars are representative of the standard
deviation of five independent experiments. (C) Right- MI8-5 CHO cells were transiently
transfected with FLAG tagged α-NAGAL, wild type and E367K mutant and treated as in
B. α-NAGAL was isolated with antisera recognizing the FLAG epitope from 10% of the
cell lysate and an equal fraction was followed by EndoH treatment where indicated.
Monoglucosylated α-NAGAL was isolated by GST-CRT pull down followed by
immunoprecipitation with FLAG antisera from 70% of the cell lysate. All samples were
resolved on a 9% SDS-PAGE reducing gel. Left- Quantification of the percentage of
reglucosylation of α-NAGAL was performed as in B. The error bars are representative of
the standard deviation of three independent experiments. (D) Right- MI8-5 CHO cells
were transiently transfected with HA tagged TCRα and treated as in B. TCRα was
isolated with antisera recognizing the HA epitope and total radiolabeled
monoglucosylated proteins with GST-CRT from 10% of the cell lysate.
Monoglucosylated TCRα was isolated by GST-CRT pull down followed by
immunoprecipitation with HA antisera from 80% of the cell lysate. All samples were
resolved on a 12% SDS-PAGE reducing gel. Left- Quantification of the percentage of
reglucosylation of TCRα was performed as in B. The error bars are representative of the
standard deviation of three independent experiments. (E) Right- MI8-5 CHO cells were
transiently transfected with FLAG tagged tyrosinase, wild type and C89R mutant and
treated as in B. Total and monoglucosylated tyrosinase were isolated as in C. LeftQuantification of the percentage of reglucosylation of tyrosinase was performed as in B.
Statistical analysis using single factor anova test gave a P value of 0.04<0.05 for WT
A1AT compared to NHK and Z mutants at 0 hr, P values of 0.001 and 0.004 <0.01 for
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WT A1AT compared to NHK and Z mutant respectively at 1 hr and a P value of 0.03
<0.05 for WT α-NAGAL compared to the E367K at 1 hr indicating that the increase in
reglucosylation of the mutants relative to WT at the indicated time points is statistically
significant.
Panels B and D are experiments performed by Nishant Patel
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Figure 2.2 Trapping WT A1AT and the endogenous substrate prosapsoin (Psap) in the
monoglucosylated state reduced their secretion efficiency and prolonged chaperone
binding.
(A) MI8-5 CHO cells were transiently transfected with WT A1AT, radiolabeled for 30
min and chased for the indicated times. 0.5 mM DNJ was added to the pulse and chase
media where indicated. WT A1AT was isolated with A1AT antisera from 12% of the cell
lysate or the media and an equal fraction was treated with PNGase F. Monoglucosylated
WT A1AT was isolated by GST-CRT pull down followed by immunoprecipitation with
A1AT antisera from 50% of the cell lysate or the media. All samples were resolved on a
9% SDS-PAGE reducing gel. (B) MI8-5 CHO cells were radiolabeled for 30 min and
chased for the indicated times. 0.5 mM DNJ was added to the pulse and chase media
where indicated. Psap was isolated with Psap antisera from 30% of the lysate or the
media. Monoglucosylated Psap was isolated by GST-CRT pull down followed by
immunoprecipitation with Psap antisera from 60% of the cell lysate. All samples were
resolved on a 9% SDS-PAGE reducing gel. The asterisk (*) indicates cleaved Psap
products. (C) Quantification of the percentage of the fully glycosylated (top band) WT
A1AT (Top panel) and endogenous prosaposin (Bottom panel) secreted into the media as
a percentage of synthesis. The error bars are representative of the standard deviation from
three independent experiments. (D) MI8-5 CHO cells were radiolabeled for 1 hr and
chased for the indicated times. Prosaposin (Psap) was isolated from 5% of the lysate with
Psap antisera, calreticulin (CRT) and calnexin (CNX) bound species from 15% of the
lysate with their respective antisera. For sequential immunoprecipitations, 65% of the
lysate was sequentially immunoprecipitated as indicated. All samples were resolved via
7.5% reducing SDS-PAGE
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Figure 2.3 Trapping NHK in the monoglucosylated state did not change its degradation
rate.
(A) MI8-5 CHO cells were transiently transfected with NHK, radiolabeled for 30 min
and chased for the indicated times. 0.5 mM DNJ was added to the pulse and chase media
where indicated. NHK was isolated with A1AT antisera from 10% of the lysate, the
media or the triton X-100 insoluble fraction. Monoglucosylated NHK was isolated by
GST-CRT pull down followed by immunoprecipitation with A1AT antisera from 80% of
the cell lysate or the triton X-100 insoluble fraction. All samples were resolved on a 9%
SDS-PAGE reducing gel. (B) Quantification of the percentage of NHK from the lysate
and the triton X-100 insoluble fraction as a percentage of synthesis. The first bar for each
time point corresponds to control conditions whereas the second corresponds to DNJ
treatment. All bands were quantified because the fully glycosylated (top band) was not
always well resolved in the later time points or the insoluble fraction. The error bars are
representative of the standard deviation of three independent experiments. (C) Cells were
treated as in panel A. 20 µM of MG132 or 100 µM kifunensine was added 4 and 2 hr,
respectively, before the pulse, and included in the pulse and the chase where indicated.
All samples were resolved on a 9% reducing SDS-PAGE gel. (D) Quantification of the
percentage of the sum of NHK from the cell lysate and the triton X-100 insoluble fraction
as a percentage of synthesis (4 hr chase). The error bars are representative of the standard
deviation of three independent experiments.

58

59

Figure 2.4 Trapping TCRα in the monoglucosylated state did not change its degradation
rate.
(A) MI8-5 CHO cells were transiently transfected with TCRα, radiolabeled for 30 min
and chased for the indicated times. 0.5 mM DNJ was added to the pulse and chase media
where indicated. TCRα was isolated with HA antisera from 40% of the lysate.
Monoglucosylated TCRα was isolated by GST-CRT pull down followed by
immunoprecipitation with HA antisera from 50% of the cell lysate. All samples were
resolved on a 9% SDS-PAGE reducing gel. (B) Quantification of the percentage of TCRα
from the lysate as a percentage of synthesis. The error bars are representative of the
standard deviation of three independent experiments. (C) Cells were treated as in panel
A. MG132 (20 µM) or kifunensine (100 µM) was added 4 and 2 hr, respectively before
the pulse, and included in the pulse and the chase where indicated. (D) Quantification of
the percentage of TCRα from the cell lysate as a percentage of synthesis (2 hr chase). The
error bars are representative of the standard deviation of four independent experiments
for no treatment and three independent experiments for MG132 and kifunensine
treatments.
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Figure 2.5 WT A1AT and prosaposin are transiently reglucosylated by UGT1 while
reglucosylation of NHK is more persistent.
(A) MI8-5 CHO cells were radiolabeled for 30 min. Where indicated, 0.5 mM DNJ was
added 15 min before the end of the pulse. DNJ was also added at the indicated times of
the chase, followed by 15 min incubation. Prosaposin was isolated with prosaposin
antisera followed by treatment with EndoH where indicated. Monoglucosylated
prosaposin was isolated by GST-CRT pull-down followed by immunoprecipitation with
prosaposin antisera. All samples were resolved on a 9% SDS-PAGE reducing gel. (B)
The quantification of the percentage of reglucosylation of prosaposin was performed as in
figure 2.1 accounting for differences in amounts of sample used for each treatment as a
percentage of EndoH-sensitive prosaposin since this represents ER localized protein
compared to EndoH-resistant protein localized to the lysosome. The error bars are
representative of the standard deviation of three or more independent experiments. (C)
MI8-5 CHO cells where transfected with either WT or NHK A1AT and treated as in A.
(D) The quantification of the percentage of reglucosylation of all bands was performed as
in figure 2.1 accounting for differences in amounts of sample used for each treatment.
The error bars are representative of the standard deviation of three or more independent
experiments.
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Figure 2.6 Reduced prosaposin is efficiently reglucosylated by UGT1.
Cells were radiolabeled for 30 min and chased for 1 hr. Where indicated, 0.5 mM DNJ
was added in the pulse and chase media. 5 mM DTT was added in the pulse media where
indicated and excluded from the chase media. Prosaposin was isolated with prosaposin
antisera. Monoglucosylated prosaposin was isolated by GST-CRT pull-down followed by
immunoprecipitation with prosaposin antisera. All samples were resolved on a 9% SDSPAGE reducing gel. (B) The quantification of the percentage of reglucosylation of
prosaposin was performed as in figure 2.1 accounting for differences in amounts of
sample used for each treatment. The error bars are representative of the standard
deviation of three or more independent experiments.
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Figure 2.7 Model for UGT1 reglucosylation of on- and off-pathway substrates.
(A) In MI8-5 CHO cells, unglucosylated glycans are transferred onto the protein. Onpathway substrates in the near-native conformations are transiently reglucosylated by
UGT1 until folding is completed (top route). DNJ addition favors accumulation of these
substrates in the UGT1 cycle supporting prolonged chaperone binding and secretion
delay (represented by the red arrows). In contrast, aberrant off-pathway substrates are
more efficiently and persistently reglucosylated by UGT1 (as indicated by the more
prominent arrows on the bottom route). The addition of the glucosidase inhibitor DNJ,
despite trapping misfolded proteins in their monoglucosylated state, does not protect
substrates from ERAD as they are efficiently extracted for degradation by a dominant
ERAD selection process (exhibited by the long red arrows). (B) In WT CHO cells,
monoglucosylated substrates generated by GlsI and GlsII trimming bind to the lectin
chaperones. After trimming of the last glucose by GlsII, substrates are released from the
lectin chaperones and continue to be recognized by UGT1 and proceed in the top or
bottom routes as described in part A.
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CHAPTER 3
THE ROLE OF MANNOSE TRIMMING IN TERMINATING
REGLUCOYSLATION CYCLES

Introduction

Glycoproteins that have gone through several reglucosylation and deglucosylation
rounds will ultimately exit the reglucosylation cycles. Those that have folded successfully
will leave the ER via vesicular trafficking, while those that have failed to fold will be
sentenced for destruction by ERAD. Nevertheless, it is still not understood how the
reglucosylation/deglucosylation cycles are terminated. One possibility is that UGT1 will
keep recognizing substrates as long as they have not folded properly. While this could be
the case, even misfolded proteins cease being recognized by UGT1, which hints that
there is another mechanism independent of the folding status of the substrate that
ultimately shuns misfolded substrates from futile and endless cycles of reglucosylation.
The failure of proteins to exit the reglucosylation cycles could have deleterious
consequences on the cell as it may result in accumulation of improperly folded substrates
in the ER which can stress the organelle and could lead to aggregation or apoptosis.
Mannose trimming has been hypothesized to be the event that results in the exit of
glycoproteins from reglucosylation cycles (Sousa et al., 1992). Trimming of mannose
residues may terminate reglucosylation by UGT1 in two ways: First, trimming of the
mannose residue that receives the glucose added by UGT1 on the A branch of the glycan
will stop reglucosylation. Second, the trimming of the mannose residues of the B and C
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branches of the glycan may decrease the affinity of UGT1 for glycans, which would
reduce the reglucosylation activity (Figure 3.1).
Evidence from previous work that mannose trimming contributes to terminating
reglucosylation cycles has been unsatisfactory and sometimes conflicting. An early study
showed that UGT1 from rat liver microsomal extracts recognized Mannose (Man)8 and
Man7 glycans at a much slower rate than Man9 (Sousa et al., 1992). The recognized
glycans still retained the glucose acceptor mannose residue of the A branch, suggesting
that the reduced number of mannose residues in the B and C branches diminishes
UGT1’s ability to recognize the modified glycan. However, the results of this assay are
inconclusive since they were performed using a cell free approach, and it is not certain
that it recapitulates the nuances of UGT1 inside the ER.
Cellular assays presented conflicting data that mannose trimming may not be the
main factor to reduce the glucose transfer by UGT1. A study using a mutant CHO cell
line MadIA214, which only transfers Man5GlcNAc2 missing most of the mannose
residues in the B and C branches, found that a major fraction of the glycans in this cell
line are glucosylated (Ermonval et al., 2001). The only way glucose containing glycans
can be formed in MadIA214 cells is via reglucosylation by UGT1. This suggests that
mammalian UGT1 may efficiently recognize glycans with low mannose content in the B
and C branches, unlike what has been previously proposed (Ermonval et al., 2001).
Nonetheless, the study did not provide a quantitative approach to directly compare the
levels of reglucosylation of high mannose to low mannose glycans.
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Support for this observation is an investigation in Saccharomyces pombe using
different strains with mutations in the glycan synthesis pathway. These strains allowed
the transfer of truncated glycans with various mannose residues content of Man9, Man7,
Man6 and Man5, and showed that UGT1 activity is not influenced by reducing the
number of mannose residues in yeast (Stigliano et al., 2011). In agreement with this, a
study suggested that the glucosyltransferase of Trypanosoma brucei may not only
reglucosylate Man9 but also Man5 containing glycans, hinting that the T. brucei
glucosyltransferase may recognize glycans with lower mannose content (Izquierdo et al.,
2009). In conclusion, it is apparent that cellular assays do not always agree with cell free
assays. Thus, it remains to be determined if mannose trimming is responsible for
triggering the release of glycoproteins from the reglucosylation cycles.
Using our previously described cell based reglucosylation assay (Chapter 2), we
investigated the hypothesis that mannose trimming prevents UGT1 mediated
reglucosylation. We found that inhibiting mannose trimming significantly enhanced the
accumulation of a reglucosylated misfolded substrate. We concluded that mannose
trimming hinders glucose transfer by UGT1 in live cells, thus causing the termination of
reglucosylation cycles. Similarly, an endogenous substrate that eventually folds also
accumulated in the reglucosylated form upon inhibition of mannose trimming, although
to a less extent than the misfolded substrate. Thus, the extent of the contribution of
mannose trimming to terminating reglucosylation cycles depends on the properties of the
substrate.
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Results
To investigate the length of persistence of substrates in the reglucosylation cycles,
we employed the cell based reglucosylation assay relying on MI8-5 CHO cells that
transfer unglucosylated glycans. Therefore, monoglucosylated substrates in MI8-5 are
generated exclusively via UGT1 reglucosylation. To trap substrates in the
monoglucosylated state, deglucosylation by glucosidase II was inhibited by addition of
the inhibitor DNJ. Cells were radiolabeled with 35S-cysteine/methionine, chased for the
indicated time, and monoglucosylated substrates were isolated by performing a GSTCRT pull down. If DNJ was to be added throughout the pulse and the chase,
monoglucosylated substrates generated by one round of reglucosylation are trapped in
that state for the length of the experiment, thus making the timing of the reglucosylation
cycles indiscernible. In the interest of determining the timing of UGT1 cycles, DNJ is
added only shortly before lysing the cells at the indicated time points (Figure 3.2).
To inhibit mannose trimming, the ER mannosidase inhibitors DMJ and
kifunensine were added throughout the pulse and the chase where indicated (Figure 3.2).
Cells were transfected with the misfolded ERAD substrate NHK A1AT, a truncated form
of A1AT resulting from a frame shift that inserts a premature stop codon. The cells were
radiolabeled for 30 min and chased for the indicated time. DNJ was added only at 15 min
before lysing the cells and performing immunoprecipitation with A1AT antibody.
Mannose trimming can clearly be seen after 1 hr of chase by the faster migrating bands,
and continues to 2 hr of chase (Figure 3.3, lanes 7, 8 and 13, 14). Upon addition of DMJ
and KIF, slower migrating bands were observed due to inhibition of mannose trimming at
1 and 2 hr (Figure 3.3, lanes 9, 10 and 15, 16). When DNJ was combined with either of
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the two drugs, A1AT NHK migrated slower (Figure 3.3, lanes 11, 12 and 17, 18). To
isolate only monoglucosylated NHK, a pull down with GST-CRT followed by
immunoprecipitation with A1AT antibody was performed. Upon addition of DNJ at each
of the indicated time points, an increase in the amount of isolated monoglucosylated
NHK can be clearly seen (Figure 3.3, compare lanes 20 to 19, 26 to 25 and 32 to 31). A
threefold increase in monoglucosylated NHK was measured upon addition of DNJ with
no chase (Figure 3.3, panel B), showing that DNJ trapped NHK in the monoglucosylated
state by inhibiting glucosidase II trimming.
The increase persisted when DNJ was added in the later time points (45 min and
105 min), indicating that reglucosylation cycles persisted up to 2 hr (Figure 3.3, panel B).
Interestingly, an increase in monoglucosylated substrates was also observed upon
addition of DMJ or KIF alone at all the time points, giving a first line of evidence that
inhibiting mannose trimming contributes to prolonging the life of NHK in the
monoglucosylated form (Figure 3.3 compare lanes 27 and 28 to 25, and lanes 33 and 34
to 31, and Figure 3.3, panel B).
Upon combining DNJ with either DMJ or KIF, a striking increase in the amount
of isolated monoglucosylated NHK was noted (Figure 3.3, compare lanes 29 and 30 to
26, and lanes 35 and 36 to 32, and Figure 3.3 panel B). The quantifications from three
independent experiments revealed an average increase of reglucosylated NHK between
eight to twelve fold approximately when DNJ was added at 45 or 105 min in the presence
of KIF or DMJ (Figure 3.4), providing a clear indication that, upon inhibiting mannose
trimming, the misfolded substrate NHK lingered longer in the monoglucosylated state,
pointing to a more persistent reglucosylation of NHK by UGT1.
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To gain further insight into how reglucosylation by UGT1 in its native
environment is terminated, we asked if mannose trimming affects reglucosylation of an
endogenous substrate, allowing us to circumvent any issues that could be associated with
protein overexpression. To that end, we investigated reglucosylation levels of the
endogenous substrate prosaposin in presence of DMJ and KIF in MI8-5 CHO cells. The
same approach was used as described above, where DNJ was added 15 min before
collecting the cells so reglucosylation cycles can be detected at the different time points.
Additionally, DMJ and KIF were added throughout the pulse and the chase. Because
prosaposin matures in the Golgi by receiving complex sugars and gets targeted to the
lysosome, we sought to distinguish between its mature and its ER resident form by using
an EndoH digestion assay (Refer to Chapter 2 for more details on the assay). The EndoH
sensitive band indicates ER resident prosaposin while the EndoH resistant band indicates
mature prosaposin that has gone through the Golgi.
Cells were radiolabeled for 30 min and chased up to 90 min, followed by lysis and
immunoprecipitation with prosaposin antibody. At the earliest time point, cells were
collected at the end of the pulse. Prosaposin was fully EndoH sensitive, indicating it is
ER resident (Figure 3.5, lanes 1 to 12). In the later time points, an EndoH resistant band
appeared indicating a fraction of prosaposin had trafficked to the Golgi, although most
prosaposin was still EndoH sensitive. GST-CRT pull down was performed and followed
by immunoprecipitation to isolate reglucosylated prosaposin. The highest level of
reglucosylated prosaposin was observed at the first time point right after the pulse, and
this level increased upon DNJ addition (Figure 3.5, compare lane 50 to 49).
Reglucosylation of prosaposin was transient as small amounts of reglucosylated
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prosaposin were isolated at 1 hr chase despite the persistence of a large fraction of
prosaposin in the ER (Figure 3.5, lanes 61 and 62). No differences were observed at the
first time point in reglucosylation levels upon addition of DMJ or KIF together with DNJ
(Figure 3.5, compare lanes 53 and 54 to 50, and Figure 3.5 panel B). However, upon
addition of DNJ at 15 min of chase, in the presence of DMJ and KIF, almost a doubling
in reglucosylation levels of prosaposin was noted (Figure 3.5, compare lanes 59 and 60 to
56 and Figure 3.5, Panel B). This increase was even higher at the later times point, as
total reglucosylated levels of prosaposin dropped in presence of DNJ alone, while it
persisted upon mannosidase inhibition (Figure 3.5, compare lanes 65 and 66 to 62, and
lanes 71 and 72 to 68, Figure 3.5, Panel B). In conclusion, mannose trimming appears to
be a general mechanism to reduce or stop reglucosylation cycles of glycoproteins.
Moreover, our approach of using an endogenous substrate, without the need for cell
transfection, represented a less invasive method to uncover a fundamental process at a
normal physiological substrate concentration.

Discussion
The process by which reglucosylation cycles are ended has been obscure for a
long time. We found that mannose trimming contributes to ending reglucosylation cycles
of both folding and misfolded substrates, but more so for misfolded substrates. It was not
surprising to see this difference between the two types of substrates as reglucosylation of
on-pathway substrates is generally more transient than that of misfolded substrates (See
Chapter 2). In addition, substrates that eventually fold undergo less extensive mannose
trimming than misfolded or ERAD substrates. Consequently, mannose trimming may not
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be the only contributor to ending their reglucosylation cycles. An alternative mechanism
is that, once these substrates reach their native or near-native state, they lose the structural
defect that UGT1 recognizes. This cannot be the case for substrates like NHK that are
terminally misfolded, and thus would require an additional mechanism such as mannose
trimming to be able to put an end to futile cycles. Thus, our data strongly points to
mannose trimming reducing the affinity of UGT1 to the substrate’s glycan.
In addition to mannose trimming reducing glucose transfer by UGT1, it could be
hypothesized that mannose trimming increases the activity of glucosidase II, which
would also result in faster exit from the reglucosylation cycles. As a result, upon
inhibiting mannose trimming, the cleavage rate by glucosidase II of the glucose residue
added by UGT1 would decrease, causing an accumulation of monoglucosylated
substrates as we observed with DMJ and KIF. However, strong evidence in the literature
suggests that this is highly unlikely, as reduced mannose content has been shown to
reduce glucosidase II activity rather than increasing it, resulting in a lengthening of the
half-life of the substrates in the monoglucosylated form. The data comes from both cell
free as well as cellular assays (Stigliano et al., 2011; Grinna and Robbins, 1980; Totani et
al., 2006; Stigliano et al., 2009; Olson et al., 2013).
Glucosidase II (Gls) is composed of catalytic (GlsII-α) and regulatory (GlsII-β,)
subunits (Stigliano et al., 2009; Trombetta et al., 1996). GlsII-β contains a mannose-6phosphate (MRH) recognition domain that binds mannose residues, which enhances the
catalytic activity of GlsII-α. An intact terminal mannose residue on the C branch of the
substrate’s glycans has been shown to be essential for the glucosidase II activity (Totani
et al., 2006; Olson et al., 2013). Thus, one of the models presented for the mechanism of
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glucosidase II is that the MRH domain of Gls-II β binds to the terminal mannose residue
of the B and/or C branch of the substrate glycan. This would position GlsII-α to bind to
the A branch and cleave the glucose residue (Olson et al., 2013). In short, it appears that
the driving force to ending reglucosylation cycles is reducing the activity of UGT1,
which is accomplished via mannose trimming, rather than increasing the activity of
glucosidase II.
It is intriguing that mannose trimming could have opposite consequences where,
on one hand, it would lead to longer residence in the reglucosylation cycle due to the
decreased activity of glucosidase II, but on the other hand, it can trigger the exit from
reglucosylation cycles due to the decreased reglucosylation by UGT1. A possible
explanation is the sequence of trimming of mannose residues in the different branches of
the glycan. We are proposing a model where UGT1 reglucosylates complete glycans on
glycoproteins, redirecting them to bind to the lectin chaperones. Mannose trimming of the
B and C could occur first, reducing glucosidase II activity but not affecting that of UGT1,
which would result in prolonged binding to the lectin chaperones and give more chances
for the protein to attempt to fold. Yet, after few attempts to fold, a protein may still be
released from the lectin chaperones by the residual activity of glucosidase II.
Subsequently, trimming of the mannose residue, which accepts the glucose of the A
branch, would inhibit UGT1 reglucosylation putting an end to the cycles. This is
supported by the major impact we observed of mannose trimming on the reglucosylation
of the substrates. Such strong correlation is expected to be due to the loss of the glucose
acceptor mannose residue of the A branch, rather than the B and C branches.
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Hence, it is essential to unravel the identity of the mannosidases responsible for
ending the reglucosylation cycles. Mannose trimming has been long known to be the
signal for targeting proteins to degradation by ERAD (Tamura et al., 2010; Liu et al.,
1999; Hosokawa et al., 2003; Hosokawa et al., 2001). Several mannosidases have been
identified in the ER that play essential roles in ERAD, though none of these
mannosidases have been studied for their role in terminating glucose transfer by UGT1.
As a consequence, any of these mannosidases is a potential candidate for playing this
role. These mannosidases are the ER α-1,2 mannosidase-I (ER manI) and its homologs
that are members of the ER degradation enhancing α-mannosidase like family (EDEMs)
1, 2 and 3 (Olivari et al., 2006; Hosokawa et al., 2003; Hosokawa et al., 2001; Mast et al.,
2005; Hirao et al., 2006). All these mannosidases and mannosidase-like proteins have
been demonstrated to accelerate degradation of misfolded substrates upon their
overexpression in mammalian cells and this overexpression is associated with increased
mannose trimming. Potentially, these mannosidases could all cooperate or act as a backup
for each other in terminating reglucosylation cycles. Alternatively, it is possible that the
different mannosidases have unique substrate preferences.
Nevertheless, evidence points that EDEM1 is the most likely candidate for
rendering glycans incompatible with UGT1 recognition site (s). In past work, a shorter
persistence of monoglucosylated substrates was noted upon EDEM1 overexpression
supporting that EDEM1 could prevent persistent reglucosylation by UGT1 (Molinari et
al., 2003). The latter observation may not necessarily be due to the mannosidase activity
of EDEM1, but simply due to EDEM1 capturing the substrate, which prevents its
reglucosylation. However, our data that mannose trimming inhibits reglucosylation
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cycles strongly hints that EDEM1 acts as a mannosidase to terminate reglucosylation.
This report is the first concrete evidence for the mechanism that terminates
reglucosylation cycles, and is not only relevant to advancing our basic understanding of
the ER quality control but also could hold the basis for designing potential therapies.
UGT1 appears to be a stringent quality control factor that retains substrates in the ER.
Yet, relieving this stringency could result in beneficial outcomes for substrates that are
retained in the ER due to minor structural defects but are otherwise functional. Since
mannose trimming reduces the reglucosylation activity of UGT1, finding drugs that could
specifically activate mannosidases responsible for trimming of the branch A of glycans
appears to be promising.

Materials and Methods
Refer to the Materials and Methods section in Chapter 2.

76

Figure 3.1 Possible mechanisms of mannose trimming in terminating reglucosylation by
UGT1.
Mannose trimming can result in ending reglucosylation by UGT1 in two ways: 1)
Trimming of the glucose acceptor mannose residue on the A branch stops reglucosylation
(Upper scheme). 2) Trimming of mannose residues of the B and/or C branches reduces
the affinity of UGT1 to the glycan, which is more likely to diminish the reglucosylation
by UGT1 than stopping it (Lower scheme).
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Figure 3.2 Experimental design to investigate the role of mannose trimming in
terminating reglucosylation cycles.
To evaluate reglucosylation by UGT1 at separate time points, DNJ is added to the cells at
only 15 min before lysis, to inhibit glucosidase II activity, and trap substrates in the
monoglucosylated state, which are later pulled-down by GST-CRT. When DNJ was
added 15 min before the pulse, it is indicated by -15 min. The rest of the time points
indicate the time DNJ was added after the start of the chase. DMJ and KIF were present
in the cells 2 hrs before the pulse, and during the pulse and the chase.
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Figure 3.3 Inhibiting mannose trimming leads to the accumulation of NHK in the
monoglucosylated state.
A) MI8-5 CHO cells were transfected with NHK and radiolabeled for 30 min. Cells were
pre-treated for 2 hrs before the pulse with 1 mM DMJ and 0.1 mM KIF, as well as during
the pulse and the chase, and 0.5 mM DNJ was added 15 min before the end of the pulse
where indicated. DNJ was also added at the indicated time of the chase, followed by 15
min incubation. NHK was isolated with A1AT antisera from 10% of the total lysate.
Monoglucosylated NHK was isolated by GST-CRT pull-down from 80% of the total
lysate followed by immunoprecipitation with A1AT antisera. All samples were resolved
on a 9% SDS-PAGE reducing gel. B) The quantification of the percentage of
reglucosylation of NHK was performed by dividing the lanes 19 to 36 from the gel in
Panel A, by the corresponding lanes 1 to 18, which were multiplied by 8 to account for
the difference of sample used. The bar graphs are representative of one experiment.
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Figure 3.4 Quantification of the increase in the reglucosylation levels upon inhibiting
glucosidase II trimming, mannose trimming, or both.
The increase in reglucosylation levels was obtained by dividing the percentage of
monoglucosylated NHK isolated from cells treated with the indicated drug(s), by the
percentage of monoglucosylated NHK isolated from non-treated cells. The error bars are
the standard deviation from three independent experiments, including the results from
figure 3.3.
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Figure 3.5 Inhibiting mannose trimming leads to the accumulation of prosaposin in the
monoglucosylated state
A) MI8-5 CHO cells were radiolabeled for 30 min. Cells were pre-treated for 2 hrs before
the pulse with 1 mM DMJ and 0.1 mM KIF, as well as during the pulse and the chase,
and 0.5 mM DNJ was added 15 min before the end of the pulse where indicated. DNJ
was also added at the indicated time of the chase, followed by 15 min incubation.
Prosaposin was isolated with prosaposin antisera from 10% of the total lysate and an
equal fraction was treated with EndoH where indicated. Monoglucosylated prosaposin
was isolated by GST-CRT pull-down from 70% of the total lysate followed by
immunoprecipitation with prosaposin antisera. All samples were resolved on a 9% SDSPAGE reducing gel. B) The quantification of the percentage of reglucosylation of
prosaposin was performed by dividing the lanes 49 to 72 by the corresponding EndoH
sensitive band in the lanes 1 to 48, which was multiplied by 7 to account for differences
of sample used. Reglucosylation was calculated as a percentage of the EndoH-sensitive
prosaposin since this represents ER localized protein compared to EndoH-resistant
protein localized to the Golgi and lysosome. The bar graphs are representative of one
experiment. Yet, similar trends were observed when the experiment was repeated.
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CHAPTER 4
THE ROLE OF FREE CYSTEINES IN SUBSTRATE RECOGNITION BY UGT1

Introduction
The environment of the ER creates favorable conditions for the oxidation of the
cysteines (Cys) of maturing proteins (Oka and Bulleid, 2013; Hagiwara and Nagata,
2012). As a result, these Cys form either intra or inter molecular disulfides. The presence
of unpaired or mispaired cysteines on maturing substrates in the ER could be an
indication of an aberration in their folding (Nishikawa et al., 2005; Hebert et al., 1996).
Thus, unpaired or mispaired cysteines of immature and misfolded substrates can be
recognized by quality control machinery proteins, such as oxidoreductases, to be retained
in the ER (Isidoro et al., 1996; Anelli et al., 2003). While UGT1 binds to non-native
glycoproteins with exposed hydrophobic residues (Sousa and Parodi, 1995; Caramelo et
al., 2003; Sousa et al., 1992), the possibility that it can select for substrates with unpaired
or mispaired cysteines has not been addressed previously in the literature. Moreover, the
previous test tube assays that looked at recognition specificities of UGT1 did not
recapitulate the redox conditions of the ER, which could affect the activity of UGT1.
Some lines of evidence indicate that UGT1 may directly or indirectly select for substrates
depending on their cysteine redox status. UGT1 is associated with an oxidoreductase,
Sep15, (Labunskyy et al., 2007; Labunskyy et al., 2009) which could bind these
substrates via disulfide bridging, and thus assist in their recruitment to UGT1. Moreover,
the cysteine rich prosaposin, which contains 16 disulfides, has been shown to be the
endogenous substrate that is most predominantly recognized by UGT1 (Pearse and
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Hebert, 2010), suggesting UGT1 might favor cysteine rich proteins. Finally, the recent
identification in the sensor region of UGT1 of the thioredoxin-like domains (Zhu et al.,
2014), which are characteristic of oxidoreductases, points to a redox mechanism of
substrate recognition by UGT1.
UGT1 has ten cysteine residues, and it is not known whether or not they could
form intramolecular disulfides. One potential mechanism of substrate recognition by
UGT1 could involve free cysteines in UGT1 that perform a nucleophilic attack on
aberrant disulfides on the substrates. Alternatively, free cysteines on immature or
defective substrates could be involved in a nucleophilic attack on disulfides on UGT1. A
third possibility could involve the abovementioned oxidoreductase Sep15 to bridge the
substrates via disulfide bond formation.
We first set out to investigate the potential role of free cysteines in substrate
recognition by UGT1. Antithrombin III (ATIII) was chosen as a model substrate, since it
is a secreted soluble glycoprotein and was shown to be efficiently recognized by UGT1 in
our preliminary assays (30% reglucosylation). ATIII pertains to the family of serine
protease inhibitors (Serpins) and inhibits the activity of thrombin and other serine
protease coagulation factors (Gettins, 2002). Thus, it plays a critical role in preventing
blood clotting, and several of its inactive mutants have been associated with thrombosis
(Perry and Carrell, 1996). ATIII has four glycosylation sites and six cysteines, forming
three disulfides. Two nested disulfides are positioned at the N-terminal end of the protein
and one disulfide at the C-terminal end (Perry and Carrell, 1996) (Figure 4.1).
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Our lab has extensively studied the maturation of ATIII and its cysteine mutants
in WT CHO cells. It was observed that ATIII with all its cysteines mutated to alanines
(ATIII Cys-less), was secreted as efficiently as wild type. Despite being efficiently
secreted, the ATIII Cys-less was incapable of binding and inhibiting thrombin
(unpublished data), indicating that ATIII Cys-less failed to fold to the active form. These
observations hinted that the absence of the cysteines from ATIII prevented its
identification as misfolded by the ER quality control machinery, thus resulting in its
release from the ER. This finding is surprising as it contradicts what is widely known in
the literature about the stringency of the ER quality control in retaining defective
substrates in the ER. Being a bona fide substrate for UGT1, we hypothesized that the lack
of cysteines from ATIII Cys-less prevented its recognition by UGT1, leading to its
erroneous escape out of the ER in-lieu of its retention.
Moreover, deletion of the most C-terminal disulfide of ATIII (ATIII C247-430A)
prevented the formation of the two N-terminal disulfides, suggesting the four cysteines of
ATIII at the N-terminus remained unpaired. Interestingly, ATIII lacking the C-terminal
disulfide was almost fully retained in the ER (unpublished data). We hypothesized that
this was due to the recognition of the unpaired cysteines by the folding sensor domain of
UGT1, which would retain the substrate in the ER. Thus, using ATIII as a model
substrate allows us to examine whether free cysteines are used by UGT1 as “handles” to
retain immature proteins in the ER.
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Results
To investigate if UGT1 uses cysteines as “handles” to retain substrates in the ER,
we compared reglucosylation levels of ATIII WT to Cys-less. ATIII WT secretes with a
half-life of 54 min, and is detected in the media 30 min after synthesis (unpublished
data). A fraction of ATIII can reach its native state in 30 min, although non-native
intermediates were observed at that time point, indicating ATIII is not fully folded yet
(unpublished data). We performed our cell based reglucosylation assay in MI8-5 CHO
cells as described in previous chapters. Since we were initially interested in comparing
the overall levels of reglucosylation rather than the timing of reglucosylation cycles,
MI8-5 CHO cells were pre-incubated with 0.5 mM DNJ for 30 min before the pulse, and
the same concentration of DNJ was maintained during the pulse and the chase. The cells
were transfected with ATIII WT or Cys-less containing a myc-tag at the C-terminus; cells
were radiolabeled for 30 min and chased for the indicated times. ATIII was isolated from
the cell lysate or the media by immunoprecipitation with myc antiserum.
Monoglucosylated ATIII resulting from reglucosylation by UGT1 was isolated by a
GST-CRT pull down, which was followed by immunoprecipitation with myc antibody.
Both ATIII WT and Cys-less were secreted efficiently (Figure 4.2, lanes 9-12 and
33-36). Quantification of secretion levels illustrated that ATIII Cys-less secretes equally
or better than ATIII WT, which indicates a lack of retention of ATIII Cys-less in the ER
(Figure 4.2, Panel B, left). These results agree with previous observations in WT CHO
cells (unpublished data). In the presence of DNJ, there was a noticeable reduction in
secretion of both ATIII WT and Cys-less compared to non-treated cells (Figure 4.2,
Compare lanes 21-24 to 9-12 and lanes 45-48 to 33-36). This is consistent with our
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previous findings that trapping a substrate in the monoglucosylated state reduces its
secretion (Chapter 2). Thus, we concluded that reglucosylation by UGT1 of ATIII WT, as
well as ATIII Cys-less, delays their exit from the ER.
To evaluate the reglucosylation activity of UGT1, monoglucosylated substrates
were isolated with a GST-CRT pull-down followed by immunoprecipitation.
Interestingly, even in the absence of DNJ, monoglucosylated ATIII WT and Cys-less
could be isolated after up to 4 hrs of chase (Figure 4.2, lanes 5-8 and 29-32). As
expected, these levels increased in the presence of DNJ, since the substrates were
maintained in the monoglucosylated form (Figure 4.2, Compare lanes 17-20 to 5-8 and
lanes 41-44 to 29-32). When comparing the level of reglucosylation, lower amounts of
monoglucosylated ATIII Cys-less were noted compared to ATIII WT, particularly at 10
and 60 min chase (Figure 4.2, Panel B, right). This could imply that the absence of
cysteines in ATIII results in less efficient recognition by UGT1 at earlier time points. We
observed a general trend of lower reglucosylation of ATIII Cys-less relative to ATIII WT
when the experiment was repeated, but more data are needed to apply statistical analysis.
We then used the ER retained ATIII C247-430A to compare its reglucosylation
and maturation to ATIII Cys-less in MI8-5 CHO cells. ATIII C247-430A lacks the Cterminal disulfide. Deletion of the ATIII C-terminal disulfide prevents the formation of
the two N-terminal disulfides, presumably by leaving the protein with four unpaired
cysteines at the N-terminus. Since ATIII C247-430A is almost fully retained in the ER,
we predicted that UGT1 is the reason for its retention, and that the reglucosylation level
of ATIII C247-430A would be higher than that of ATIII Cys-less.
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The reglucosylation assay with the ATIII C247-430A construct was carried out as
described above (Figure 4.3). Consistent with previously observed results in WT CHO,
ATIII C247-430A was secreted at a lower level than ATIII Cys-less in untreated cells
(Figure 4.3, Compare lanes 9-12 to 33-36, and Panel B, left). Monoglucosylated ATIII
Cys-less and ATIII C247-430A were detected even in the absence of DNJ, and their
amounts increased in the presence of DNJ as would be expected (Figure 4.3, Compare
lanes 17-20 to 5-8 and 41-44 to 29-32). Higher levels of monoglucosylated ATIII C247430A compared to ATIII Cys-less were observed at 10 min and 240 min, although the
trend was not consistent for the other time points (Figure 4.3, Panel B, right). The
elevated levels of reglucosylated ATIII C247-430A could indicate that UGT1 might
favor the ATIII C247-430A mutant due to the presence of unpaired cysteines. However,
since this trend was not the same at all the time points, it is difficult to make a definitive
conclusion. Moreover, the higher reglucosylation of ATIII C247-430A is not sufficient to
be solely responsible for the retention of this mutant in the ER.
The approach used so far compares the reglucosylation levels after one round of
reglucosylation. This approach does not give information about the timing of
reglucosylation, nor its persistence. Finding if reglucosylation cycles are persistent could
provide an explanation of the retention of substrates in the ER. Thus, instead of adding
DNJ throughout the pulse and the chase, DNJ was added in a shorter time window before
lysing the cells. A window of 30 min rather than the previously used 15 min was chosen
to ensure that sufficient ATIII was trapped in the reglucosylated form (See Chapter 3,
Figure 3.2 for experimental design). The time point -20 min indicates DNJ was added 20
min before the start of the chase, and the cells were chased for 10 min in the presence of
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DNJ (Figure 4.4). The rest of the time points refer to the time DNJ was added where
indicated after the start of chase. The persistence of reglucosylation as well as secretion
efficiency of ATIII C247-430A was compared to that of ATIII WT in MI8-5 CHO cells.
In the absence of any drug treatment, ATIII WT was secreted significantly better than
ATIII C247-430A (Figure 4.4, compare lanes 9-12 to 33-36, Panel B, left). The addition
of DNJ showed that reglucosylation of ATIII C247-430A persisted, particularly when
DNJ was added 90 min after the chase (Figure 4.4, Compare lane 44 to 20).
Quantification of reglucosylated ATIII showed higher levels of reglucosylation of ATIII
C247-430A by comparison to ATIII WT when DNJ was added after 30 and 90 min of the
start of the chase. In summary, it appears that ATIII C247-430A is more persistently
reglucosylated than ATIII WT, which suggests that UGT1 persistently reglucosylates ER
retained substrates with unpaired cysteines.

Discussion
The folding sensor domain of UGT1 has been well known to recognize exposed
hydrophobic regions on immature substrates. Another hallmark of non-native
glycoproteins is the presence of unpaired or mispaired cysteines. Here, we addressed the
possibility that UGT1 can recognize proteins containing unpaired cysteines using ATIII
as a model substrate.
We first analyzed whether the presence of cysteines in ATIII is important to its
recognition by UGT1 by comparing reglucosylation of ATIII WT to Cys-less. We found
that reglucosylation of the misfolded ATIII Cys-less was marginally lower than that of
ATIII WT. This does not necessarily indicate that cysteines are not playing a role in
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substrate recognition by UGT1, but the preference of UGT1 for misfolded substrates that
we observed previously (Chapter 2) could be compensating for their absence, explaining
why no major differences were observed.
Chaperones in the ER, such as BiP, can act as a backup for the UGT1/CNX
cycle, to retain misfolded proteins in the ER (Pieren et al., 2005). However, it appears
that the retention of misfolded ATIII Cys less by BiP has failed, suggesting that ATIII is
not a BiP substrate. Whether ATIII is a BiP substrate or not should be the subject of
further investigation.
To directly address if unpaired cysteines contribute to substrate recognition by
UGT1, we compared the levels of reglucosylation of ATIII Cys-less to C247-430A.
ATIII C247-430A was proposed to carry four free cysteines at its N-terminus. This was
supported by the observation that, on non-reducing gels, it runs to the same position as
reduced ATIII WT (unpublished data). Further studies are needed to confirm that the four
cysteines at the N-terminus of ATIII C247-430A are unpaired, which can be done by
comparing gel mobility shifts of ATIII C247-430A that is modified or not with
maleimide functionalized PEG (Polyethylene glycol) groups that react with free thiols.
The presence of these four unpaired cysteines did not seem to cause much of an increase
in ATIII C247-430A reglucosylation by comparison to ATIII Cys-less. Yet, it seems to
support more persistent reglucosylation. That the level of persistent reglucosylation
observed is sufficient to explain the ER retention of ATIII C247-430A is still an open
question and these preliminary results require further confirmation.
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Future work should focus on determining if having a single free cysteine in ATIII
would result in an increase in reglucosylation relative to ATIII Cys-less. We examined
this possibility in our preliminary studies, but our results were not conclusive due to the
fact that ATIII mutants with single Cys at certain positions formed dimers, which would
present double the number of glycans to be possibly modified by UGT1 compared to the
monomer. Reglucosylation of the monomer must be assessed with non-reducing samples
obtained from the cell-based reglucosylation assay, where only the bands corresponding
to the monomer are quantified.
According to a recent study, the crystal structure of a portion of the folding sensor
domain of UGT1 revealed a domain with a thioredoxin-like fold and two additional
domains with a thioredoxin-like fold were predicted (Zhu et al., 2014) (Figure 1.5,
Chapter 1). Thioredoxin-like domains are found in oxidoreductases and are characterized
by a CXXC motif that catalyzes oxidation or isomerization of disulfides (Oka and
Bulleid, 2013; Rutkevich and Williams, 2011). However, UGT1’s two most N-terminal
thioredoxin-like domains lack cysteines, and the third thioredoxin-like domain contains a
single cysteine, suggesting that these domains are unlikely to have an oxidoreductase
activity. However, a redox mechanism cannot be excluded yet. Future work should
determine the functions of these domains.
The selenocysteine containing protein Sep15 is known to bind to UGT1 and has
been proposed to act as an oxidoreductase in the ER (Korotkov et al., 2001; Labunskyy et
al., 2005). That Sep15 can modulate UGT1 activity has not been tested. It is possible that
Sep15 can first recognize non-native substrates with unpaired cysteines, and then present
them to UGT1 for reglucosylation.
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Taken together, the apparent contribution of free Cys to substrate retention in the
ER implied from our preliminary data, and the association of UGT1 with Sep15 strongly
point to a redox mechanism that could define the function of UGT1. Future work could
uncover a previously unpredicted mode of action of UGT1 in ER quality control.

Materials and Methods
Refer to the Materials and Methods section in Chapter 2
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Figure 4.1 Schematic of antithrombin (ATIII)
ATIII is 464 amino acids in length. The signal sequence (in black) covers the first 32
amino acids and is cleaved upon translocation of the protein into the ER. It contains four
glycosylation sites (branched structures) and six cysteines (red ovals). The six cysteines
form three disulfides, two nested disulfides at the N-terminal end of the protein, and one
disulfide at the C-terminal end of the protein.
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Figure 4.2 Comparison of reglucosylation and secretion of ATIII WT to Cys-less
A) MI8-5 CHO cells were transiently transfected with ATIII WT or Cys-less,
radiolabeled for 30 min and chased for the indicated times. 0.5 mM DNJ was added
throughout the pulse and chase where indicated. ATIII was isolated with myc antibody
from 20 % of the cell lysate or the media. Monoglucosylated ATIII was isolated by GSTCRT pull down followed by immunoprecipitation with myc antibody from 70% of the
cell lysate. All samples were resolved on an 8% reducing SDS-PAGE. B) Quantification
of reglucosylation and secretion levels of ATIII WT and Cys-less. The percentage of
reglucosylation of ATIII WT was obtained by dividing lanes 17-20 by the corresponding
lanes 13-16, which were multiplied by 7.5 to account for differences in sample used.
Similarly, the percentage of reglucosylation of ATIII Cys-less was obtained by dividing
lanes 41-44 by the corresponding lanes 37-40, multiplied by 7.5. The secretion
percentage of ATIII WT was obtained by dividing lanes 9-12 by lane 1, and the secretion
percentage of ATIII Cys-less by dividing lanes 33-36 by lane 25. The bar graphs are
representative of one experiment.
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Figure 4.3 Comparison of reglucosylation and secretion of ATIII Cys-less to C247-430A.
A) MI8-5 CHO cells were transiently transfected with ATIII Cys-less and C247-430A,
radiolabeled for 30 min and chased for the indicated times. 0.5 mM DNJ was added to the
pulse and chase media where indicated. ATIII was isolated with myc antibody from 20 %
of the cell lysate or the media. Monoglucosylated ATIII was isolated by GST-CRT pull
down followed by immunoprecipitation with myc antibody from 70% of the cell lysate.
All samples were resolved on an 8% SDS-PAGE reducing gel. B) Quantification of
reglucosylation and secretion levels of ATIII Cys-less and C247-430A. The percentage
of reglucosylation of ATIII Cys-less was obtained by dividing lanes 17-20 by the
corresponding lanes 13-16, which were multiplied by 7.5 to account for differences in
sample used. Similarly, the percentage of reglucosylation of ATIII C247-430A was
obtained by dividing lanes 41-44 by the corresponding lanes 37-40, multiplied by 7.5.
The secretion percentage of ATIII Cys-less was obtained by dividing the quants from
lanes 9-12 by lane 1, and the secretion percentage of ATIII C247-430A by dividing lanes
33-36 by lane 25. The bar graphs are representative of one experiment.
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Figure 4.4 Comparison of the persistence of reglucosylation, and secretion levels of
ATIII WT to C247-430A
A) MI8-5 CHO cells were transiently transfected with ATIII WT and C247-430A,
radiolabeled for 30 min and chased for the indicated times. 0.5 mM DNJ was added to the
cells at the indicated time relative to the start of the chase. ATIII was isolated with myc
antibody from 20 % of the cell lysate or the media. Monoglucosylated ATIII was isolated
by a GST-CRT pull down followed by immunoprecipitation with myc antibody from
70% of the cell lysate. All samples were resolved on an 8% reducing SDS-PAGE. B)
Quantification of reglucosylation and secretion levels of ATIII WT and C247-430A. The
percentage of reglucosylation of ATIII WT was obtained by dividing lanes 17-20 by the
corresponding lanes 13-16, which were multiplied by 7.5 to account for differences in
sample used. Similarly, the percentage of reglucosylation of ATIII C247-430A was
obtained by dividing lanes 41-44 by the corresponding lanes 37-40, multiplied by 7.5.
The secretion percentage of ATIII WT was obtained by dividing lanes 9-12 by lane 1,
and the secretion percentage of ATIII C247-430A by dividing the quants from lanes 3336 by lane 25. The bar graphs are representative of one experiment.
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CHAPTER 5
CONCLUSIONS AND FUTURE DIRECTIONS

A great load of secretory and membrane proteins is constantly trafficking through
the ER. To cope with this heavy flow, the eukaryotic ER has evolved an intricate network
of factors that reduce folding errors or dispose of the failures. In this highly crowded
environment, UGT1 stands at the intersection between the folding and the degradation
routes. Thus, determining if UGT1 can direct proteins to these different routes is of
paramount importance in expanding our understanding of the ER quality control.
The function of UGT1 in the ER has been extrapolated from past work that
studied the properties of UGT1 in cell free assays. While these approaches were
necessary and indispensable for propelling our understanding of the role of UGT1, there
has been a lack of cellular assays that addressed its function, particularly in mammalian
cells. Thus, we adopted an assay that allowed us to directly assess the reglucosylation
activity of UGT1, and its impact on substrate maturation in intact cells. In this thesis, we
uncovered fundamental details of the mechanism of UGT1 in the surveillance of
glycoproteins. Moreover, our findings opened the door into new avenues of investigation,
which could grant a better understanding of protein maturation and trafficking.

The properties of substrates recognized by UGT1
We found that UGT1 recognized both substrates that fold successfully in the ER,
such as prosaposin or wild type α1-antitrypsin and substrates deemed misfolded, such as
the ERAD clients NHK and A1ATZ. This suggests a less discriminatory role of UGT1
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than previously proposed in the literature and that UGT1 can recognize both proteins
capable of attaining their native fold and those that are deemed misfolded, although
UGT1 seemed to favor misfolded substrates. Furthermore, the orphan subunit of the Tcell receptor complex TCRα, which is an ERAD substrate, and disease mutants of
tyrosinase and α-N-acetylgalactosaminidase were also recognized by UGT1 (Chapter 2,
Figure 2.1). While we have used several substrates with different biophysical properties
and topologies, testing additional model substrates would broaden the scope of this
conclusion, particularly by comparing the reglucosylation of bona fide ERAD substrates
to their wild type counterparts.
To further define the extent to which the requirement for recognition by UGT1
correlates with the folding efficiency of the substrate, future work should focus on
comparing reglucosylation of fast folding to slow folding substrates. Fast folding
substrates are expected to be less efficiently recognized by UGT1 because they stay in the
form of incompletely folded intermediates and reside in the ER for a brief time, while the
opposite applies for slow folding substrates. RNase and CFTR consist of well-studied
model substrates for fast and slow folding proteins in the ER, respectively (Ward and
Kopito, 1994; Geiger et al., 2011). We have attempted to use RNase, but we have faced
the problem of severe hypoglycosylation. Thus, further optimization or different
substrates are needed to perform this study.
Although the literature provided us with a number of good model substrates that
helped us to expand our understanding of the properties of UGT1, this does not
necessarily make them ideal substrates. In addition to the folding status of the substrate,
features of the substrate like size, topology (membrane or soluble), number of glycans,
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number of cysteines or even the overall hydrophobicity could determine whether or not a
substrate will be recognized or even be favored to be modified by UGT1. Although all
the wild type glycoproteins that we have tested so far were reglucosylated by UGT1,
there have been differences in the reglucosylation efficiency, with prosaposin and ATIII
seemingly being the most efficiently recognized. The identification of endogenous
substrates of UGT1, and classification of these substrates based on their biochemical
properties, could uncover features favored by UGT1. A proteomics approach with our
GST-CRT pull down assay might provide clues for trends in substrates selection of
UGT1. Yet, instead of the MI8-5 CHO cell line, ideally, this experiment should be done
in an ALG6 deficient human cell line that transfers glucose deficient N-linked glycans to
substrates (Shrimal and Gilmore, 2015). Taken together, a proteomic analysis would help
to further clarify the basis of substrate selection by UGT1, and could uncover an even
larger role of UGT1 in protein homeostasis in the ER.

The implications of the localization of UGT1 for the persistence of reglucosylation
cycles
We found that UGT1 transiently reglucosylated wild type substrates, while it
reglucosylated misfolded substrates more persistently (Chapter 2, Figure 2.5.). The latter
finding is in agreement with the previously determined localization of UGT1 beyond the
rough ER, which positions UGT1 to reglucosylate substrates at later time points.
However, it is contradictory with the observation that reglucosylation can be seen at early
time points, suggesting UGT1 is also active early in the maturation pathway. The data in
the literature are not clear about the location of UGT1 within the ER, as it is suggested to
be more concentrated in either the smooth ER, ER exit sites or the pre-Golgi intermediate
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compartment (Zuber et al., 2001; Gilchrist et al., 2006). Separation of the rough and
smooth ER fractions from MI8-5 CHO (Gilchrist et al., 2006), followed by isolating
monoglucosylated substrates like NHK or WT A1AT by the GST-CRT pull-down from
each fraction could help in determining whether reglucosylation can begin in the rough
and persist in the smooth ER. Moreover, super resolution microscopy techniques can help
to further clarify the detailed location of UGT1 in the ER, and determine if it co-localizes
with the elements of the reglucosylation cycle.

Defining the players that terminate reglucosylation cycles
We have determined that mannose trimming of glycoproteins contributes to their
removal from reglucosylation cycles (Chapter 3, Figure 3.3 and 3.5). Several questions
arise from this observation. What is the identity of the ER mannosidases responsible for
mannose trimming? Are all these mannosidases required? Which branches of the glycan
are trimmed to reduce or stop reglucosylation?
While the identity of the mannosidases responsible for terminating
reglucosylation cycles is not known, several mannosidases have been identified in the ER
such as ER mannosidase I and the mannosidase-like proteins EDEM1-3. Whether or not
one of these mannosidases could be responsible for removing substrates from
reglucosylation cycles can be determined either by knocking down or overexpressing
each of them individually in MI8-5 CHO then performing the reglucosylation assay to
look at persistence of substrates in the reglucosylation cycles. Since these mannosidases
could act as a back-up for each other, it might be necessary to knock-down or
overexpress a combination of multiple proteins.
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Defining which branch of the glycan is trimmed to reduce or arrest
reglucosylation might be more challenging. Mass spectrometry can be used to determine
the composition of the glycan(s) of different substrates upon over-expression or
knockdown of mannosidases, though this is far from trivial. Alternatively, our cell based
reglucosylation assay can be performed, but with cell lines that transfer glycans with
reduced mannose composition and lack glucose residues such as the MadIA214 CHO
cells, which only transfers Man5 GlcNAc2, a glycan missing the branches B and C
(Ermonval et al., 2000; Ermonval et al., 2001). If these glycans get reglucosylated
efficiently in the cell based reglucosylation assay, this would indicate that the B and the C
branches do not influence glycan recognition by UGT1. If a reduction in reglucosylation
occurs upon overexpression of mannosidases in these cells, it would point to a trimming
of the A branch. This approach can provide direct evidence, not only to which branch in
the glycan is responsible for reducing or stopping substrate recognition by UGT1, but
also to the identity of the mannosidase that performs the trimming.

Free thiols potentially represent a new mechanism of selection of immature
substrates by UGT1
Using ATIII as a model substrate, we have accumulated some preliminary
evidence suggesting that free thiols on an incompletely folded or misfolded substrate
contribute to its recognition by UGT1 and its subsequent ER retention by the lectin
chaperones. Another possibility is that UGT1 could have unpaired cysteines that mediate
the recognition of substrates with aberrant disulfides. Modification with PEG groups
functionalized with thiol reactive moieties such as PEG-maleimide would confirm that
UGT1 has free cysteines if a mobility shift is observed on an SDS-PAGE. In addition,
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non-reducing gels would demonstrate whether or not UGT1 and the substrate form
covalent intermolecular disulfides if a complex is detected on the gel.
Alternatively, the interacting partner of UGT1, Sep15, which is hypothesized to
be an oxidoreductase, could recognize substrates with unpaired or mispaired cysteines,
and subsequently present them for reglucosylation by UGT1 (Labunskyy et al., 2005;
Labunskyy et al., 2007). By performing our cell-based reglucosylation assay in MI8-5
CHO with over-expression or knockdown of Sep15, we can define if Sep15 plays a role
in recognizing substrates and passing them over to UGT1.
Finally, it would be of interest in future experiments to investigate the function of
the thioredoxin-like domains of UGT1. These domains do not contain any cysteines
except for one in the third domain thus, it is unlikely that they have a catalytic function in
oxidation or isomerization of disulfide bonds (Zhu et al., 2014).Yet, they could still be
responsible for substrate recognition by UGT1. They can be expressed individually in
mammalian cells to investigate if they still maintain interaction with UGT1 substrates.
Moreover, although the crystal structure of the third domain has been solved, that of the
first two domains is just predicted (Zhu et al., 2014). In addition, the solved crystal
structure of the third domain is from the C. thermophilum, which shares only 35%
homology with UGT1 (Zhu et al., 2014). Thus, the observed thioredoxin-like fold in C.
thermophilum UGT1 may not certainly be shared by its human homolog, making it
essential to solve the crystal structure of human UGT1.
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Summary
To conclude, we have determined that reglucosylation of wild type substrates by
UGT1 results in delay in their trafficking and in their prolonged binding to lectin
chaperones, while reglucosylation of misfolded substrates does not affect their
degradation by ERAD. In addition, misfolded substrates are more persistently
reglucosylated than wild type substrates and seem to be favored by UGT1. Moreover,
mannose trimming contributes to ending reglucosylation cycles. Future work should
focus on determining the mannosidases responsible for this trimming, and the branches of
the glycans that are trimmed. Lastly, preliminary data and evidence from the literature
indicates that free Cys could be hallmarks that UGT1 uses to select immature
glycoproteins for reglucosylation. Dissecting the details of the involvement of free Cys in
recognition by UGT1 could uncover a new mechanism of UGT1 in protein quality
control that potentially involves other players in the ER.
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